Disclosure Ethics

Mass CE course #C33541

4 ethics credits
About This Course

This course considers the ethical standards related to health insurance policy disclosure.

We know that health insurance brokers have an ethical obligation to disclose several things:

First, they must honestly explain policy terms;
Second, they cannot leave out important information;
Third, they must honestly quote the price.

But does the broker’s ethical responsibility end with these three obligations? Should an ethical broker disclose additional information? Specifically, do health insurance brokers have a disclosure responsibility to educate their clients about the workings of our healthcare system, or should the broker ‘let the buyer beware’ of them?

Let’s remember that the ultimate product we sell is healthcare. Insurance is simply (simply?) the means of financing healthcare services. We know that our clients will ultimately purchase healthcare services – examinations, surgeries, medical treatments and the like. Our products facilitate access to, and use of, these services: health insurance is not an ‘end’ product in and of itself. The ‘end’ product is good health.

This raises a key question: can brokers differentiate health insurance from health care? In other words, can brokers reasonably claim that their jobs involve only making financial resources available to clients for medical care, but not the end-use for which clients use this money?

In this text, we will suggest that they cannot reasonably make this claim.

Instead, we will suggest that healthcare financing (insurance) is inextricably tied into medical care. The ‘benefits advisor’ should, in other words, advise on the benefits that clients will access. The ‘ethical benefits advisor’ will help clients understand the likely impact of using various services.

We’ll discuss this at great length, shortly. But in this Preface, let’s look at a warning issued by Bernard Rosof, Chairman of Huntington Hospital in New York: ¹

‘Often people with generous insurance plans can run up large bills and face life-threatening complications from unnecessary care. Those problems include back

¹ Washington Post, September 29, 2009, Connolly. Italics added. Many other commentators have made similar suggestions.
surgeries that result in wound infections when physical therapy might have been a more effective treatment.’

Rosof suggests several things here.

- First, that people with ‘generous insurance plans’ may receive different care from people with less generous plans.
- Second, that some of the different care is ‘unnecessary’.
- Third, that this ‘unnecessary care’ can lead to harm.
- Fourth, that this happens ‘often’.

Does Rosof – the Chairman of a hospital - mean that patients with certain types of health insurance actually receive unnecessary and harmful care as a function of their health insurance? Might some types of health insurance actually result in more patient harm than other types? Could you, as a broker, unintentionally cause some harm to your clients?

Rosof’s quote raises a number of ethical questions for brokers.

- How should they respond when faced with evidence that their policies (i.e. the products that they sell) may lead to patient problems and harms?
- Should they simply ‘let the buyer beware’?
- Or should brokers live up to a higher ethical standard?

The knowledgeable broker knows that we sometimes overuse our medical system. Researchers like Professor Jonathan Skinner of Dartmouth Medical School who have studied this phenomenon suggest that above a certain level of care:

*There is just no evidence that doing more helps. At best you do the same, and in some cases you actually do worse [due to infections, errors, patient fatigue, etc]*

This is apparently the thrust of Mr. Rosof’s comments.

We want our clients to receive the right care – not too little or too much. Too much care, or overtreatment, may lead to poorer patient results. Indeed, some Dartmouth Medical School researchers, among others, have discovered that mortality rates go up as patients receive more and more medical care. Dr. Elliott Fisher, a Dartmouth Medical School researcher and Director of the Dartmouth Institute for Health Policy and Clinical Practice, did an exhaustive study of medical spending patterns and discovered that

---

hospitals that spent the most and did the most for patients had a 2 – 6% higher mortality rate ³ concluding

The additional medicine patients are getting in the high-cost regions is leading to harm. ⁴

More care led to more patient risks from error, infection and fatigue without any compensating medical advantages.

Here’s our potential patient cycle: patients with ‘generous insurance plans’ (Mr. Rosof’s words) may receive unnecessary care. That care, according to Dr. Fisher, corresponds to higher mortality rates. How should an ethical broker react to this kind of information? What should he/she do with this information? What ethical disclosure standard should he/she adopt?

**New Health Insurance Plans and the Medicare Modernization Act of 2003**

make broker ethical disclosure even more important

Two trends over the past 10 years highlight the need for brokers to disclose likely medical impacts ethically.

**First,** deductibles have increased dramatically. In the early 2000s, a ‘high deductible’ plan might include an annual $250 deductible. In 2017, many (most?) plans include a $1000 annual deductible with some exceeding $2000. This places an increased economic burden on clients who want to avoid wasting their own money on unnecessary care.

In the past brokers might have considered the ‘unnecessary care’ problem a minor issue. Yes, they may have thought, some excessive care may be unnecessary but other so-called excessive care might prove useful to patients. No individual actually paid for it since virtually all plans included first dollar coverage and the harms from excessive care were not widely known or understood.

Today’s high deductibles, though, create an economic cost to patients. Each unnecessary MRI can waste several hundred dollars, money more usefully spent in

---


other ways. This makes the broker more responsible for helping clients identify and avoid unnecessary care today than ever previously.

Second, more companies try self funding, with some carriers offering self funded or partially self funded plans to groups as small as 50. In self funded arrangements, each wasted dollar of medical care comes directly from the company’s bottom line.

These two trends have fundamentally changed the broker’s responsibilities. Not only must the broker assemble an appropriate benefits package for each client and keep clients in compliance with state and federal regulations, but brokers today must try to control healthcare spending. Among the ways to do this: teach people how to identify and avoid unnecessary medical care.

Disclaimer

We discuss various medical procedures, treatment protocols and outcomes in this course. We do so as insurance brokers and educators, not as physicians or medically trained professionals. We at HealthInsuranceCE, LLC are not medically trained or licensed and provide no medical advice herein. You should always consult your own physicians about medical care. You should not interpret anything contained in this course as medical advice, and you should not rely on anything contained in this course as a basis for medical decision making.

Education Differs from Advocacy and Advice

This is an education course. We do not advocate any particular ethical position. Nor do we advocate any particular approach to medicine.

Rather, our goal is to stimulate broker’s thinking about these issues. We will present data, ethical dilemmas and alternative solutions. We hope this course will help you consider your own ethical standards, for in the end, you must make your own decisions about ethical behavior.

We will base our ethical positions on standards that have existed for hundreds (thousands?) of years. We will trace the origins of these standards and comment on their applicability to today’s health insurance brokers. Why do we take this approach?

Most ethicists – the people who discuss ethical behavior - have a strong background in historical ethical thought, often as articulated in traditional Judeo-Christian positions. Many of these positions have become codified in our laws and insurance regulations.
Our regulatory injunctions against theft, for example, may be seen as directly descending from Judeo-Christian ethical positions. While some of the ethical positions discussed in this course are based on traditional Judeo-Christian ideas, we do not advocate any particular religion or even religion itself. Rather, we use these traditional ideas because they have served as the ethical basis of western civilization for thousands of years. Living according to Judeo-Christian teachings is generally synonymous in our society with living ethically.

We aim, in this course, to stimulate your thinking about ethical issues, rather than to direct brokers to act in any specific way. We offer ethical positions not dogmatically, but rather as a teaching guide.
Table of Contents

Overview ........................................ Page 2
Introduction to the Problem ................. Page 8
A Comparison of Two Ethical Standards .... Page 14
Some Ethical Advice Issues ................. Page 25
Case Study ................................... Page 33
A Discussion with a Benefits Administrator Page 46
If the Broker ‘lets the buyer beware’ then who will ‘do his clients a favor’? Page 50
How Should an Ethical Broker Proceed? .... Page 56
Case study: Did the health insurance industry act ethically after 2000? Page 60
Introduction to the Problem
Some information that an ethical broker should disclose

Here are some examples. Note when reading these that we take no position on whether or not the benefits outweigh the risks or vice versa. We simply provide data here and pose questions about the broker’s ethical responsibilities to inform his/her clients.

First, an overview. A massive 2013 study and important 2015 book concluded that 40% of established medical practices – and maybe even half - are ‘ineffective or harmful’. 5 This study wasn’t published in some unknown or disrespected journal, by unknown researchers. Instead it was published in the Mayo Clinic Proceedings, a highly respected medical publication, written by lead author Dr. Vinay Prasad, a Senior Fellow at the National Cancer Institute and National Institutes of Health, and reviewed in the New York Times.6

Prasad and his team reviewed every article written in the New England Journal of Medicine between 2001 and 2010 and found 363 that examined an established medical practice. 146 of them, about 40%, were found to be ineffective or harmful when put to a rigorous comparative test, 38% were beneficial and 22% unknown. Examples include:

- Prolonged antibiotics for patients with persistent symptoms and history of Lyme disease
  - No benefit found in, 2 randomized, placebo-controlled, dble blind studies
- Low calcium diet for patients with history of kidney stones vs. diet low in animal protein and salt (but normal calcium)
  - After 5 yrs, low calcium group had double rate of kidney stones
- Intensively lowering blood sugar in Type 2 diabetics to reduce cardiovascular events
  - Low blood sugar group (A1c < 7%) sustained for 3.5 yrs increased mortality without fewer cardiovascular events compared to more permissive goal
- And about 140 more

Dr. Prasad summarized his findings this way in a You Tube video attached to the Mayo article:

Patients who are embarking on procedures, screening tests or diagnostic tests should really try to ascertain whether or not those tests are based on good

---

5 Prasad, A Decade of Reversal, Mayo Clinic Proceedings, August 2013 and Ending Medical Reversal written with Adam Cifu

6 Bakalar, Medical Procedures May Be Useless or Worse, NY Times, July 26, 2013
evidence. Of all those things we’re doing that lack good evidence, probably about half of them are incorrect.

The fundamental problem, he said to the New York Times, edited for space here:

Medical procedures

‘all sound good if you talk about the mechanisms. You have cholesterol-clogged arteries, it makes sense that if you open them up it will help. But when that was studied, it didn't improve survival.”

Patients, like to talk about mechanisms. “They tend to gravitate toward the nuts and bolts — what does it do, how does it work? But the real question is: Does it work? What evidence is there that it does what you say it does? What trials show that it actually works? You shouldn’t ask how does it work, but whether it works at all.”

Our ethical dilemma starts here.

- Who discloses this type of information – that about half of all medical treatments are ineffective or harmful – to your clients?
- Should brokers ‘let their clients beware’ and assume that physicians and other medical professionals will provide the necessary information?

We’ll address that question in detail later in this course. For now, though, a very brief answer: No – leaving all medical education to physicians has been conclusively proven ineffective. See Mr Rosof’s comments above, along with Dr. Fisher’s.

Relying on doctors to educate patients has generated a waste factor in American healthcare of up to about 30% of all spending. Brokers – responsible to employers for both assembling benefit programs and helping control costs – cannot leave all medical education to physicians and the internet.

Of course, since brokers are not licensed medical professionals, they can only provide a specific type of consumer education. We’ll articulate that below. But the message so far – from Mr. Rosof, Dr. Fisher and Dr. Prasad: leaving medical education exclusively to physicians has been proven to raise costs, raise risks and generate sub-optimal outcomes. The broker has, at minimum, an ethical responsibility to disclose this fact to clients.

**Second, some specifics.** Various highly respected medical organizations publish lists of ‘Things Providers and Patients Should Question’ on ChoosingWisely. (All brokers should be aware of ChoosingWisely, our opinion.) Among things to question, per this initiative:
Stress tests on asymptomatic patients. The American College of Cardiology states bluntly on ChoosingWisely ' 

- Don’t perform stress cardiac imaging in the initial evaluation of patients without cardiac symptoms unless high-risk markers are present.
- Don’t perform annual stress cardiac as part of routine follow-up in asymptomatic patients.
- This practice may lead to unnecessary invasive procedures without any proven impact on patients’ outcomes.
- Stress tests on insured patients costs about $200 - $400 per test – often an unnecessary expense that can lead to unnecessary procedures (according to the College of Cardiology)
- Our ethical question: who tells this to your clients?

Allergy tests. The American Academy of Allergy, Asthma and Immunology, consisting of 6500 members in 60 countries, developed this statement for ChoosingWisely

- Don’t perform indiscriminant battery of immunoglobulin tests in evaluation of allergy…Appropriate diagnosis is based on the patient’s clinical history
- Random allergy testing usually doesn’t help, can lead to unnecessary lifestyle changes…give up foods, such as wheat, soy, eggs, or milk, end up with nutritional problems
- Who advises patients to ask their physicians about these risks?

Back MRIs. The American Academy of Family Physicians, representing 105,000 physicians, bluntly states on ChoosingWisely

- Don’t do imaging for low back pain within the first six weeks unless red flags are present
- …Imaging of the lower spine before six weeks does not improve outcomes but does increase costs
- Red flags include, but are not limited to, severe or progressive neurological deficits or when serious underlying conditions such as osteomyelitis are suspected.

But the American Academy of Family Physicians isn’t alone in questioning the utility of back MRIs when someone feels back pain. Here’s the North American Spine Society, 7500 members from orthopedic surgery, neurosurgery, radiology and physical therapy, also on ChoosingWisely

- Don’t have advanced imaging (e.g., MRI) of the spine within the first six weeks for non-specific acute low back pain in the absence of red flags.
• In the absence of red flags, advanced imaging within the first six weeks has not been found to improve outcomes, but does increase costs.
• Red flags include, but are not limited to: trauma history, unintentional weight loss, immunosuppression, history of cancer, intravenous drug use, steroid use, osteoporosis, age > 50, focal neurologic deficit and progression of symptoms.
• Again, who tells this to your clients?

The American College of Physicians representing 126,000 physicians agrees with this official statement on ChoosingWisely

• Don’t obtain imaging studies in patients with non-specific low back pain.
• In patients with back pain that cannot be attributed to a specific disease or spinal abnormality following a history and physical examination (e.g., non-specific low back pain), imaging with plain radiography, computed tomography (CT) scan, or magnetic resonance imaging (MRI) does not improve patient outcomes.

And the American Society of Anesthesiologists – Pain Medicine, comprised of 50,000 members who advocate for patients who need anesthesia or pain medicine, goes even further

• Avoid imaging studies (MRI, CT or X-rays) for acute low back pain without specific indications.
• Imaging for low back pain in the first six weeks after pain begins should be avoided in the absence of specific clinical indications (e.g., history of cancer with potential metastases, known aortic aneurysm, progressive neurologic deficit, etc.).
• Most low back pain does not need imaging and doing so may reveal incidental findings that divert attention and increase the risk of having unhelpful surgery.

Why do we make such a big point about back imaging and list so many medical societies that recommend against having such a test when you first feel the pain? Because our national rate of MRIs has increased from about 56 per thousand people in 2000 to 98 per 1000 people in 2010. 7 Clearly the medical community has not educated patients about the risks of unnecessary MRIs.

Here's the excess-MRI issue on a broader scale, comparing the number of MRI’s per 1000 Americans to the number per 1000 British, French or Canadians.

7 OECD data
Some MRIs are clearly useful. Based on the evidence from other countries that are demographically and socio-economically like us, having about 50 scans per thousand of population seems about right. That’s about what other advanced countries – with slightly better infant mortality and longevity data – have. We currently do about double that. British, French and Canadian life expectancies slightly exceed ours and their infant mortality rates slightly trump ours. The relative lack of MRIs has not, apparently, harmed their national statistics.

Here’s a very rough estimate of the economic costs of those additional or unnecessary MRIs: $30 billion annually.

The calculation: MRIs cost about $2000 each, according to New Choice Health, a website that compares medical care prices.  

That’s $2000 for each of the 50 unnecessary MRIs per thousand of us…and there are about 310 million of us!

Remember the key point here: the medical community is unable to cut the rate of apparently unnecessary MRIs on its own. This excess harms our employer clients who pay for the unnecessary utilization as well as employees who may actually be harmed by the excessive scans. Our customers pay – either individually through their deductible or self funded companies by spending their own money unnecessarily.

**Should brokers ‘let the buyer beware?’**

Ethical brokers, from our point of view, should tell their clients about their risks of receiving excessive, unnecessary and potentially harmful medical care.

Ethical brokers should make resources like ChoosingWisely available to their clients.

Ethical brokers should inform their clients that the medical community has questions about the utility of certain medical practices.

And ethical brokers should help their clients learn the key questions to ask their physicians to avoid medical harms.

We’ll discuss the origins of these ethical standards next.
A comparison of two ethical standards

The Traditional View of Business Ethics: ‘Do unto others as you would have them do unto you’ and ‘Love thy neighbor as yourself’ are two fundamental ethical dictates of the Judeo-Christian tradition. We – Americans coming from these traditions and teaching – believe that we have responsibilities to treat others as we would want them to treat us.

Some Judeo – Christian Business Ethical Positions on Disclosure

Let’s start with the first commercial transaction in the Torah or Old Testament, in which Abraham laid down the ‘full disclosure’ commercial principle.9

Many commentators think that this ethical principle is of fundamental importance, given its prominent position in the Bible. They argue that if some other principle was more important, then it would have appeared first.

The story of Abraham purchasing a burial plot for his wife Sarah – who died while on an out-of-town business trip with her husband - shows the importance of full disclosure by the product seller to the product buyer. The haggling over land takes five steps in Genesis 23: 3 - 20:

Step 1: Abraham explains to the local people what he needs in vague terms – a burial plot for his wife. He does not stipulate where or exactly what kind of burial plot and indeed, doesn’t know the local burial plot details or issues;
Step 2: The sellers offer ‘the choicest of our burial places’;
Step 3: Abraham considers this (perhaps even goes on a guided tour of choice burial places) then asks for ‘the cave of Machpelah…which is at the end of [the sellers] field’, and offers to pay ‘full price’;
Step 4: The sellers confirm that they have exactly what Abraham wants ‘the field and cave that is in it’;
Step 5: The buyer and seller ultimately agree on the land and price and transact the purchase in public ‘in the presence of the sons of Heth, before all who went in at the gate of his city’.

Note the similarity to health insurance policy sales:

9 This genesis of this discussion comes from www.torah.org Business Ethics: The Challenge of Wealth, Parchas Chayei Sarah, Parchas Metzora, Parshas Shoftim and Responsa-Vayigash
Step 1: the Buyer explains what he/she needs in vague terms – a policy to cover my family’s medical needs, perhaps with some specific issues in mind, or a policy to cover all our full time employees;
Step 2: the Broker says ‘we have many quality plans available’ and explains them;
Step 3: the Buyer considers several options, then stipulates what he/she wants;
Step 4: the Broker confirms that a specified policy contains the desired benefits;
Step 5: the Buyer enrolls by signing a contract.

It was clear from Abraham’s negotiations that he had the opportunity to view the land and cave prior to purchasing. The seller had helped him learn about the land, pointing out the choicest burial place. Indeed, the seller may even have warranted the land: ‘none of us will withhold from you his burial place’, thereby confirming that this was, in fact, burial property.

The seller apparently understood that Abraham – ‘a foreigner and a visitor’ – did not know all details about local burial plots. The seller therefore helped Abraham learn everything that he needed to know so he could make a wise, informed purchase.

The story of Abraham’s burial plot purchase shows that the seller has an ethical responsibility to educate the buyer about the product. Abraham was a foreigner, needing advice about local burial procedures and options, which plot to purchase, etc. The seller provided that education.

The message here: sellers who educate buyers are ethical. This begins the ethical tradition of full disclosure. There was no ambiguity about the land, the location or the use. No confusion about exactly what Abraham bought…because the seller provided such a thorough and detailed education.

‘Let the Buyer Beware’ is Unethical

The lesson about this transaction: in traditional Judeo-Christian ethics there is no concept of ‘let the buyer beware’. The seller taught Abraham everything he needed to know about local burial plots, made very clear to Abraham exactly what he was buying and made his declarations publicly.

‘Let the buyer beware’ assumes that all parties to a commercial transaction have the same information regarding price, quality, use, location, comparative markets, etc. This was clearly not true for Abraham, the ‘foreigner and visitor’. The seller could have taken advantage of his lack of knowledge to swindle him, but did not. The seller educated the buyer. This is the ethical business lesson of Genesis 23: 3 – 20.

‘Let the Buyer Beware’ Assumes that All Parties have Equal Abilities to Understand the Information Available
In the Biblical case, Abraham was only able to understand the intricacies of burial plots after being educated by the seller. Is this concept still valid today? Can ‘let the buyer beware’ serve as a valid basis for commercial transactions?

The answer is no. Traditional Judeo-Christian ethics remain valid today, for two main reasons.

**Reason 1: Sellers and Buyers Rarely Have Exactly the Same Information**

The seller generally knows his / her products far better than the buyer, as was the case of Abraham’s burial plot seller or an insurance broker. The seller deals in this market, for this product, far more frequently than does the typical buyer so understands it better.

This was clearly the case for Abraham, whose expertise did not include detailed knowledge of local burial plots. It’s also the case in our industry, where the health insurance broker regularly reads industry information provided by carriers and regulators while the buyer only purchases health insurance one time per year.

**Reason 2: Sellers can understand their product information far better than the buyer can**

This is primarily because the health insurance broker has studied healthcare issues in far greater depth than the typical buyer. Even if the buyer has very good access to information, he / she often lacks the background and context in which to place that information.

Again, this is similar to Abraham’s situation. He was a merchant, with expertise in his own arena, not in burial plots. He was not in a strong position to understand burial plot issues without additional education.

In fact, Abraham might not even know which questions to ask the burial plot seller. He needed guidance from a trusted source here.

Our clients are similar to Abraham. They are accountants, schoolteachers or fishermen with expertise in their own fields, not healthcare. Lacking the broker’s healthcare education and background, they are less able to understand healthcare details and issues than the broker.

Thus for these two reasons – that the broker has better access to product information and a better ability to understand that information – today’s health insurance salesperson has an ethical responsibility to educate the client. Just like Abraham’s burial plot seller.
Do Your Fellow A Favor

Traditional ethics goes even further. *Parshas Shoftim*, a commentary on ethical principles, stipulates that ‘He who does not *do his fellow a favor*, is not of the sons of Abraham’ for ‘we force one to act contrary to the selfishness of Sodom’.

This places an even greater ethical burden on the seller. Not only must he / she educate the buyer and make full disclosure, but the seller must *do his fellow a favor* and highlight problems with the healthcare system that may occur.

Why would traditional Judeo-Christian ethics place such a burden on sellers?

There appears some thinking that these burdens ultimately work to the advantage of the seller. If all sellers act ethically as described above, then it becomes very easy to sell products to buyers because buyers would have a very high degree of confidence in the seller’s representations.

**Translating These Ideas to Product Sales and Business**

One way that many of us would like to be treated: we would like people with expertise to share their expertise with us. Let’s look at a simple example of ‘treating others as you would want them to treat you’ – an interaction with a car mechanic.

When I have a question about my car, I ask my local mechanic – i.e. my car expert.

I seek his advice because he has had years of experience working with cars. He has an expertise that I do not share. He can differentiate serious from minor problems and advise me if and when to get my car fixed. A good mechanic answers my questions when I ask them. He treats me as he would want to be treated were conditions reversed.

But here’s a slightly more complicated case: when my mechanic changes my oil and notices a problem with my car, I expect him to inform me. My local mechanic recently told me, for example, that – since I was coming up on 100,000 miles - I should schedule a tune-up and install new brake pads. I appreciated his advice: he treated me well, which means ‘he did unto me as I hope I would do unto him’ were conditions reversed.

I would be very unhappy with a mechanic who told me after a serious accident ‘Yes, I noticed that your brake pads were worn out, but I decided not to tell you’. Here the expert did not share his expertise. I thought that he would ‘do unto me as I would do unto him’ were conditions reversed and he let me down.

An ethical expert shares his/her expertise with clients. An unethical expert does not.
Note some issues with this lack of disclosure:

1. Since he did not tell me that there was a problem with my car, I assumed that there was, in fact, no problem;

2. The underlying issue here is definitional. I define a good mechanic as one who looks out for my interest. Part of his job is to be my 'car advisor' and offer advice about how best to maintain my car.

He, apparently, defines his job much more narrowly, simply as fixing things that I ask him to fix, but no more.

3. His definition of 'good mechanic' puts an enormous burden on me. I must ask after every oil change for example, a number of specific questions about my car's operation. Are the brake pads good? Is the air filter working properly? Does the head gasket leak? Are the brake rotors in good condition? Are the tires balanced?

Unless I ask, he will not disclose.

4. My interest in developing a long term relationship with this mechanic is very weak. I don't trust him to look out for my interests. I worry that I may fail to ask the right questions and have an avoidable accident as a result.

5. As a result, I will probably switch to a different mechanic. After all, they just fix cars. They all use the same parts. They all – more or less – repair things that have broken.

I will switch because I define 'good mechanic' as someone who looks out for my interest, who helps me be proactive in maintaining my car and who fixes things that brake.

The fundamental issue between me and my mechanic: I want him to share his expertise with me, in addition to fixing my car. I want him to do me a favor, not let me beware!
Case Study
Insurance Broker Ethical vs. Non Ethical Behavior

Several years ago I had a poignant interaction with an insurance professional over this *information disclosure issue*. The situation:

I had considered changing a liability insurance policy (written by an out-of-town agent) so got a quote from my long-term local P & C agent. He informed me by phone that he had a better policy at a lower price than my current plan. He summarized some key points and said he could bind it on my verbal approval. I trusted him, so agreed.

He also suggested that I cancel my existing policy, which I also did.

After a detailed policy review (a week or two later) I decided that the new policy was not as comprehensive as the previous one. I re-activated the old policy with the out-of-town agent, and informed my long-term local agent by email that I wanted to terminate the new one.

He never cancelled my new policy. Instead, several months later, he told me that neither I nor the other broker had submitted the cancellation request on the correct form. (It then took numerous phone calls and significant upset to correct the problem.)

Note the different definitions at work here. My local agent defined his job as getting quotes, processing bills and filing the correct forms. He took the ‘let the buyer beware’ approach, apparently thinking that the burden of looking out for my interests fell on me or on others. He would sell me the policies that I requested, and nothing more.

I defined his job as ‘looking out for my interests’, or ‘doing to me as I would do for him were roles reversed’ - which included informing me that I needed to file a specific form to achieve my cancellation goal. I had no way of knowing which form to file absent his input; he had specific expertise and product knowledge that he failed to share with me. He ‘let the buyer beware’ to an upsetting end.

This destroyed my ability to trust his advice. What other information, I wondered, would he also leave out? What avoidable harms might I endure? What unnecessary problems would I face? In short, why should I pay him to advise me when he takes the ‘let the buyer beware’ approach?

Needless to say, he fairly quickly lost my home and auto insurance accounts!
Unequal Knowledge about Health Insurance

What does ‘unequal knowledge about the healthcare system’ mean?

Brokers typically know a great deal more about our healthcare system than do their clients. Among the areas of broker expertise:

- Underwriting guidelines
- Provider cost data (at least rough and crude measures)
- Outcome data (again, rough and crude measures)
- Treatment complication data (assuming a well informed broker)

Brokers typically know much more about our healthcare system than their clients do. Brokers, for example, read industry journals and understand underwriting practices. Their clients, typically, do not.

Is a health insurance broker like the car mechanic above who has specialized knowledge? Is he like the P & C broker who failed to share his expertise with me? What disclosure responsibilities does a health insurance broker have?

We suggest adopting the ‘do your fellow a favor’ ethical position, based on the Judeo-Christian roots described above. This has served as the moral and ethical foundation of western civilization for thousands of years.

Business Ethics = Business Efficiency
Ethical Practices = Good Customer Service

Traditional ethics equates business ethics with business efficiency. The ethical standards are really instructions for successful businesspeople.

This approach follows directly from the two fundamental ethical dictates of Judeo-Christian religions described above: ‘Do unto others as you would like done to yourself’ and ‘Love thy neighbor as yourself’.

Effectively, this means sellers should give clients excellent advice about the products they are selling.

In doing this, traditional ethics advises us to educate our clients as we would like them to educate us, were conditions reversed.

If everyone followed these ethical principles, in other words, we would have a very well functioning business economy. The principles can be seen as a manual for how to prosper in business. We’ll read its various ethical teachings in this light.
Ethical sellers – i.e. those who follow these traditional principles - would not have to prove their honesty or credibility. They could concentrate, instead, on selling products. This is very efficient: sellers could focus on their income generating activities (i.e. sales) rather than spending time explaining or justifying their personal ethical standards, or establishing personal credibility. They would thus generate higher incomes.

Ethical practices, as we have discussed above, also equal good customer service. Would you prefer to purchase something from a seller who ‘lets the buyer beware?’ Or would you prefer that the seller ‘do you a favor?’

Abraham apparently preferred the latter. His burial plot sellers were, apparently, credible, as there is no mention of him searching for other plot sellers. He did not shop around for a ‘better deal’. He was – apparently – satisfied with his seller’s ethical positions, and the quality of education they offered, so chose to do business with him.

My car mechanic – the one who advises me that my brake pads are thin or that I need a tune up at 100,000 miles – also takes this ethical position. He ‘does his fellow a favor’ by advising of problems that may occur, so I can fix them promptly. When I find a mechanic like this – who looks out for my interest – I stay with him.

Not so for my long ago local P & C agent. He did not share the mechanic’s business approach. He chose to offer the minimum client education and not to inform me of the specific policy cancellation process. He ended up operating his business less one client.

As with burial plot sellers, car mechanics and P & C agents, so with health insurance brokers. Brokers who ‘do their fellow a favor’ act ethically; those who ‘let the buyer beware’ do not.

**Is it enough simply to describe the health insurance policy in detail?**

Such a description would include a discussion of copayments and deductibles, pre-existing condition exclusions if any, available providers, prescription drug coverage, price etc and then show alternative products and describe them.

Though this may satisfy some customers, it does not satisfy all the ethical dictates discussed above: Simply describing the insurance policy in detail does not satisfy the traditional ethical dictates discussed above.

The broker also has an ethical responsibility to describe policy implications and healthcare systemic problems that may harm the customer.

**How Much Should Brokers Disclose?**
The question posed in Parchas Shoftim above, in the discussion of *do the fellow a favor* remains: *How much should a seller disclose about a product to a customer?*

It is unclear from Genesis 23 exactly *how much* information Abraham’s burial plot seller provided. He apparently provided a great deal, and probably all that was necessary in that circumstance. But we get into a gray area when applying the lessons of Genesis to more complicated transactions, like health insurance policy sales.

**How Should the Broker Educate the Buyer?**

Clearly a broker should not give medical advice. That’s outside the realm of his / her licensed authority.

Rather, we suggest that health insurance brokers have an educational responsibility to offer clients information indicating that, for example, there is a disagreement over the use of back MRIs in the medical community: The ethical broker can advise clients that educational resources exist.

The ethical broker’s goal in educating the client: help the client become an informed consumer of medical services. The ethical broker becomes a resource for his/her clients.

**Some Samples**

Just as a public library makes information on a wide range of subjects available to the general public, so the ethical broker can make information on medical care available to clients.

We have tried this is out in our live classes. One telling example: we distribute information on the rates of Caesarian births by local hospital.

I often start the discussion by asking ‘How do you decide which hospital to use for child delivery?’ Most women respond that they use the hospital recommended by their obstetrician.

‘When do you choose an obstetrician?’ I then ask. Answers range from ‘I use my gyn for obstetrics, and I’ve known my gyn for years’, to ‘I use the obstetrician recommended by my friends, relatives or primary care physician.’ In any case, women report that they generally have an obstetrician on board quite early in their pregnancy.
I then present data on the various rates of Caesarian births in different local hospitals. Here's a partial list of Massachusetts hospitals published in 2010: 

<table>
<thead>
<tr>
<th>Hospital Name</th>
<th>Rate of Caesarian Births</th>
</tr>
</thead>
<tbody>
<tr>
<td>Holy Family, Methuen</td>
<td>47%</td>
</tr>
<tr>
<td>Melrose-Wakefield</td>
<td>46%</td>
</tr>
<tr>
<td>South Shore</td>
<td>44%</td>
</tr>
<tr>
<td>Metro West</td>
<td>42%</td>
</tr>
<tr>
<td>Signature</td>
<td>41%</td>
</tr>
<tr>
<td>Holyoke</td>
<td>22%</td>
</tr>
<tr>
<td>Tobey</td>
<td>19%</td>
</tr>
<tr>
<td>North Adams Regional</td>
<td>18%</td>
</tr>
<tr>
<td>Heywood</td>
<td>16%</td>
</tr>
</tbody>
</table>

The next comment that typically arises in live classes: there must be medical differences among the patients in those hospitals. For example, women at high risk will use Holy Family more frequently than Heywood.

But wait, I caution. You said that you use the hospital where your obstetrician has admitting privileges. You choose your obstetrician before you had any delivery complication issues (generally). Now you've changed your story!

In fact, the analysis of these treatment rate differences does not indicate that women presented with such different medical needs. Rather, according to Dr. Lauren Smith, medical director of the Massachusetts Department of Public Health, the reason for the rate differences include:

A complex array of factors….including how they organize the staffing of their labor and delivery units, what are the resources that might be available.

Patient need differences played a minor role and did not explain the vast differences in Caesarian rates.

Indeed, Smith, the Massachusetts DPH Medical Director, went on to say that in a similar analysis performed from 2004 – 2006 – where hospitals were divided into three groups based on the complexity of obstetrical care they provided – the caesarean rates varied widely within the groups.

---

10 Massachusetts Births 2008, Massachusetts Department of Public Health, Bureau of Health Information, Statistics, Research and Evaluation, Division of Research and Epidemiology, March 2010

11 Boston Globe, 6/7/10
The New Hampshire insurance department looked into similar C-section rate disparities among New Hampshire hospitals and concluded, in the official report

There are no obvious reasons that explain why c-sections are higher at one NH hospital vs. another … [and] … there does not appear to be a relationship between c-section rates and health status. 12

Or, stated more bluntly in a 2013 Harvard School of Public Health study

the same woman would have a different chance of undergoing a c-section based on the hospital she chooses 13

Might physicians at some hospitals perform the procedures with which they are the most comfortable and ignore patient presentations that suggest a different treatment is more appropriate?

One hospital might overperform a treatment with which it feels comfortable, while another might underperform one with which it feels uncomfortable. Hospitals might staff up and organize their resources around a particular treatment and then gain a comfort level with it – just as Dr. Smith of the Mass DPH suggests.

Why might a hospital organize itself to perform more or fewer Caesarians? A number of factors may impact on this decision, including financial incentives, religious or philosophical orientations or entrenched hospital bureaucratic interests. Patient need differences, according to the analysis by the Mass DPH, play a relatively minor role in all this.

Brokers learning this information in our live classes – especially the pregnant ones – are generally quite astonished. I often ask ‘do you think your clients would like to know this?’ The typical answer: Yes, of course.

In our ethical terms, these brokers would like to treat their clients as they would like to be treated. They verbalize – though not in so many words – a desire to ‘do their fellow a favor’.

12 A Commercial Insurance Study of Vaginal and Cesearean Section Rates at New Hampshire Hospitals, State of New Hampshire Insurance Department, April 1, 2011

13 Pregnant women’s likelihood of cesarean delivery in Massachusetts linked to choice of hospitals, Harvard School of Public Health News, March 19, 2013
Some Ethical Advice Issues

**Geographic treatment variation** means that the *same* patient, with the *same* medical condition, might receive *different* care in *different* geographical regions.

In other words, a retiree living in Fort Myers, Florida and experiencing lower back pain, for example, is about twice as likely to have back surgery as the same person living in Miami.\(^{14}\)

Or a person suffering from angina might be 70% more likely to have angioplasty in Elyria, Ohio, than the same person living in Akron – about 50 miles away. \(^{15}\)

Or a person living in Florence, South Carolina with a chronic medical condition may be about 50% more likely to be hospitalized than the same person, with the same medical condition, in nearby Charleston, SC. \(^{16}\)

How can this be?

**Treatment Variation and the Broker's Ethical Advisory Role**

Below, we'll explain why treatment variations exist. But first, we seek to make two key points to brokers:

1. No region of the US suffers from a lack of medical resources, though in some rural areas people need to travel longer to receive care than do urban dwellers.

   This suggests that treatment intensity above the minimum may be unnecessary and wasteful, potentially causing more harm than patient benefit.

2. No entity in the US healthcare distribution system has a specific responsibility to inform patients of this situation. Indeed, many healthcare providers are either ignorant of this or have financial incentives (fee for service) to provide more care.


Note how the broker shares long-term financial interests with the employer-client. The client may switch carriers and change provider networks while staying with the same broker.

As such, the broker wants his/her clients to receive the best medical care, at the best possible price, over the long term.

The broker may have an ethical reason (‘do your fellow a favor’) and a financial reason (remember how Judeo-Christian teachings equate business ethics with business efficiency) to advise patients about the risks of treatment variation.

**Why Variations Exist**

Perhaps the key source of geographic treatment variation data is the Dartmouth Atlas of Healthcare, which uses Medicare data to determine the amounts of medical care received in different regions of the US. The Atlas describes and documents the vast variations in medical care available to patients in the US. You can access this information at [www.DartmouthAtlas.org](http://www.dartmouthatlas.org).

One reason for variations in medical treatment between regions is the supply of medical resources – i.e. hospital beds per capita, radiological equipment per capita, specialists per capita, etc.

Here’s how the Dartmouth Atlas describes this situation: 17

Regional variation in capacity reveals the irrational distribution of valuable and expensive health care resources. Capacity represents the capital investments and labor that permit the delivery of medical services.

Two types of capacity determine the majority of health care costs.

The first is hospital capacity, including the number of general and intensive care beds, imaging devices, and procedure suites like operating rooms and cardiac catheterization labs.

Health care labor is the second and related component of capacity, and includes the physicians, nurses, allied health professionals and administrative staff who work in hospitals and physician practices.

Unfortunately, the distribution of capacity fails to reflect the regional need for health care, either for beds or for physicians and hospital staff.

Even after controlling for differences in age and sex, some regions had more than twice the number of beds per capita than other regions.

More beds means that patients are more likely to receive their care during a hospital admission, with greater costs, and a higher likelihood of hospital-acquired infections and medical errors.

Higher physician supply offers little benefit in population health or in patients' satisfaction with access to care and with the care received.

In other words, as the supply of hospital beds increases, the number of patients admitted also increases…but outcomes, as measured by mortality rates, speed at which patients return to functional status or patient satisfaction with medical care do not improve.

In fact, the mortality rates go up as patients receive more medical care, not down!

Here’s Elliott Fisher of Dartmouth Medical School, describing how regional spending rates vary, along with mortality rates:

For every 10% increase in spending [comparing one US region to another], relative risk of death in 5 years increased.\(^{18}\)

The reason, again: above a certain amount of care (say, the US regional minimum), additional medical care increases risks of error, infection or patient fatigue with no concomitant benefit increases.

Note that Fisher and the other Dartmouth studies work primarily with Medicare data, as that’s the most comprehensive US healthcare data source available.

Why might regions with more hospital beds and physicians per capita of the population provide more medical care?

**Roemer’s Law**

Researchers have studied the impact of bed supply on hospitalization rates since the 1950s, at least. The pioneer of this research, Dr. Milton Roemer, first studied the impact of expanding the bed supply in a study of an upstate New York town in 1957 – 8.\(^{19}\)

---

\(^{18}\) Fisher, Implications of Regional Variations in Medicare Spending Part 2, 2003

\(^{19}\) Milton Roemer, Bed Supply and Hospital Utilization: A Natural Experiment, Hospitals, 35 (1961)
Here’s what Roemer found: in 1957 this town (Roemer doesn’t name it, so unfortunately, we can’t verify his data) had one general hospital with 139 beds. The average daily occupancy was 108 (78%) suggesting some excess bed capacity.

The hospital was apparently satisfying the medical needs of this community reasonably well. Roemer based this conclusion on his reading of the local newspapers, which reported few, if any, stories about inadequate hospital resources.

In 1959, the town opened a new general hospital with 197 beds. Roemer doesn’t explain why, but notes that there was no population change, no new industries moving to town and no major disease epidemics. Apparently the town took advantage of some financing available to build a new hospital and close the old one.

Almost overnight, the hospital occupancy grew to 137 – a 26% increase!

Roemer suggested that physicians responded to this increased bed supply by hospitalizing patients in 1959 that they would not have hospitalized in 1958.

His conclusion: ‘the supply of hospital beds in a community or state is the major determinant of the hospital utilization.’ The amount of treatment variation due to bed supply: about 26%.

Roemer’s Law – that a hospital bed built is a hospital bed occupied – suggests that the availability of excess hospital beds may account for 26% of all US healthcare spending.

**Other Studies Reinforce Roemer’s Conclusion**

Fisher, in his major 2003 studies, concluded that

> Up to a third of medical care is devoted to services that do not provide any detectable benefit.

He studied the distribution of medical resources by region, and compared patient treatment patterns and mortality rates. His studies have not been refuted. Indeed, other researchers have found the same expenditure patterns.

Here, for example, is a comparison of Medicare spending in El Paso and McAllen, Texas, using 2006 data: ²⁰

<table>
<thead>
<tr>
<th></th>
<th>McAllen</th>
<th>El Paso</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average Medicare spending/capita</td>
<td>$14,900</td>
<td>$7,500</td>
</tr>
</tbody>
</table>

²⁰ Atul Gawande, Cost Connundrum, New Yorker, September 2009
McAllen Medicare beneficiaries had, compared to El Paso:

- 50% more specialist visits
- 20% more abdominal ultrasounds
- 30% more bone density tests
- 60% more stress tests with echocardiography
- 2/3 times more pacemakers, cardiac bypass operations and coronary artery stents

Yet the McAllen demography appeared virtually identical to the El Paso demography, with no significant mortality or longevity differences:

<table>
<thead>
<tr>
<th></th>
<th>McAllen</th>
<th>El Paso</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average household income</td>
<td>$40K</td>
<td>$36K</td>
</tr>
<tr>
<td>Poverty rate</td>
<td>27%</td>
<td>27%</td>
</tr>
<tr>
<td>% Hispanic</td>
<td>80%</td>
<td>77%</td>
</tr>
</tbody>
</table>

Why do McAllen Medicare recipients get more medical care than El Paso folks? The answers appear to include (a) regional treatment norms and (b) the availability of medical specialists.

**Would Your Clients Like to Know This?**

The number of specialists varies significantly by region, even if the population demographics do not.

Here, for example, is the distribution of physicians in ‘high spending regions’ vs ‘low spending regions’ (spending levels calculated on a per capita basis) per 1000 Medicare beneficiaries in 2003: 21

<table>
<thead>
<tr>
<th></th>
<th>High Spending Region</th>
<th>Low Spending Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rates per 1000 Medicare beneficiaries</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specialists</td>
<td>78</td>
<td>57</td>
</tr>
<tr>
<td>Sub Specialists</td>
<td>44</td>
<td>27</td>
</tr>
<tr>
<td>Surgeons</td>
<td>56</td>
<td>44</td>
</tr>
<tr>
<td>GPs / Family practitioners</td>
<td>27</td>
<td>36</td>
</tr>
</tbody>
</table>

High spending regions have more specialists per capita and fewer primary care physicians. They enjoy (enjoy?) higher medical costs.

---

21 Maggie Mahar, Money Driven Healthcare, page 170
But researchers who have studied the medical outcomes suggest that this additional spending generates no better medical outcomes. Here’s Fisher again, from his same studies:

we found no evidence that the pattern of practice observed in higher spending regions led to improved survival, slower decline in functional status or improved satisfaction with care.

Thus the type of medical care received by people in the higher spending regions – defined as having more beds and more specialists – does not impact positively on patients.

As a region gets more hospital beds and more medical specialists, the medical costs increase. But patient outcomes do not improve.

Two other researchers from Dartmouth, Katherine Baicker and Amitabh Chandra, arrived at an even stronger conclusion:

Researchers have found that underlying population risk (i.e. disease factors) does not seem to drive the presence of specialists and that outcomes are not improved by increased access to these specialists. 22

Specialists don’t set up their shops based on the disease epidemiology in a region – i.e. based on patient demand for their services. They set up their shops in regions where the local medical culture indicates that patients will access their services.

For patients, having easy access to a greater number of specialists does not generate better outcomes. Yet – often – this is exactly what your clients want in a health insurance policy: easy access to a wide range of specialists.

Kenneth Thorpe of the Rollins School of Public Health at Emory University takes this one step further. He suggests that having access to more specialists means that patients will use more specialists and that this process may lead to unnecessarily high mortality rates. Dr. Thorpe was Deputy Assistant Secretary for Health Policy in the U.S. Department of Health and Human Services from 1993 to 1995. His research shows that

A typical Medicare beneficiary sees two primary care physicians and five specialists working in four different practices…who rarely coordinate the care they deliver. Because of this structural deficiency, patients with chronic illnesses

22 Baicker and Chandra ‘Medical Spending, the Physician Workforce and Beneficiaries Quality of Care’ Health Affairs, April 7, 2004
receive only 56% of clinically recommended medical care. That gap in care may explain a nontrivial portion of morbidity and excess mortality. 23

‘Excess mortality’ is a death rate higher than the underlying demographics would predict.

Why does access to more specialists lead to this ‘excess mortality’? We’ll turn to the final researchers in this section, Peter Muennig and Sherry Glied, both of the Mailman School of Public Health at Columbia University. Muennig and Glied asked ‘What Changes in Survival Rates Tell Us About US Health Care’ and conclude that:

Unregulated fee-for-service reimbursement and an emphasis on specialty care may contribute to high US health spending, while leading to unneeded procedures and fragmentation of care…Fragmentation of care leads to poor communication between providers sometimes conflicting instructions for patients, and higher rates of medical errors. 24

Here’s our summary:

1. As we provide a higher supply of hospital beds and specialists, we generate higher utilization (Roemer’s Law);

2. This does not improve outcomes or generate higher patient satisfaction with care (Fisher);

3. Indeed, specialist location decisions are not a function of patient need or the epidemiologic demand for specialist services (Baicker);

4. But the availability of excess beds and specialists leads to systemic fragmentation and excess mortality (Thorpe);

5. The reason for excess mortality is poor communication between and among the excess supply of specialists (Muennig).

Should You Inform Your Clients?
How Would an Ethical Broker Behave?


Armed with this type of information, an ethical broker would inform his/her clients (a) that treatment variations exist and (b) some ways the client can protect him/herself from receiving excessive and unnecessary care that may pose unnecessary risks and generate unnecessary costs.

One way for the client to protect him/herself: access information from the Dartmouth Atlas, Medicare or other sources to determine if he/she is *likely* to receive unnecessary care.

Your client can then discuss this with his/her physician(s). The client and physician can, together, review the available data and then discuss appropriate treatment strategies.

Alternatively, of course, you can let your client beware…
Case Study

If you were a customer, would you want your broker to advise you of this?

We have, so far in this course, made two fundamental points.

First, that traditional business ethics requires brokers to ‘do their fellow a favor’, which, in the health insurance brokerage arena, means to advise their clients about various systemic risks;

Second, we’ve discussed one of those systemic risks: regional treatment variation or the chance that people will receive excessive and unnecessary care in certain regions, and have higher medical risks as a result.

In this Chapter, we will look at three types of medical care to see the role that local treatment orientations play. You can find the same situation in all other states.

Do you think your clients would like to know this?

Some Geographic Background

(This information is specific to Massachusetts. The methodology, however, applies to all states.)

Massachusetts is broadly divided into 5 hospital referral regions by the Dartmouth Atlas of Healthcare.

Dartmouth defines hospital referral regions as ‘regional health care markets for tertiary medical care that generally require the services of a major referral center.’

Among the 5 Massachusetts hospital referral regions, 2 use out-of-state hospitals for tertiary care: extreme western Massachusetts uses the Albany, New York hospitals, and extreme southern Massachusetts uses Providence, Rhode Island hospitals. These two regions contain relatively small populations. As such, and for simplicity here, we will focus on the 3 most heavily populated regions in Massachusetts: the Boston area, the Worcester area and the Springfield area.
The **Boston area** is generally defined by patients living in, or east of, Middlesex and Norfolk counties. This population tends to use the downtown Boston teaching hospitals – Massachusetts General Hospital, the Brigham and Women’s Hospital and the Beth Israel Hospital – for major tertiary care.

The **Worcester area** is generally defined by patients living in Worcester county. This population tends to use the University of Massachusetts Medical Center in Worcester for major tertiary care.

The **Springfield area** (Springfield is in Hampden County) is generally defined by patients living in Franklin, Hampshire, Hampden and Berkshire counties. This population tends to use the Springfield hospitals for major tertiary care.

We’ll evaluate the treatment tendencies of each region for three common acute procedures: mastectomies, leg amputations and coronary angioplasty.

**Mastectomies**

Dartmouth’s raw data indicate the following rates for mastectomies in these three Massachusetts hospital referral regions:
Boston area --- 8.7 per 10,000 female Medicare beneficiaries
Springfield area – 5.5 per 10,000
Worcester area – 5.0 per 10,000

Here’s a graph showing the differences.

**Regional Treatment Tendencies:**
**Mastectomies**
Source: Dartmouth Atlas. Data downloaded Feb 2011

(If you’re seeing this in black and white, Boston is the left bar, Springfield is the center bar and Worcester is the right bar.)

This chart shows that Boston area female Medicare beneficiaries have about a 60% greater likelihood of having a mastectomy than Springfield women, and about a 74% greater likelihood of having a mastectomy than Worcester women.

This, claim many, is not particularly surprising. The Boston area hospitals include several Harvard Medical School affiliated teaching hospitals and the world famous Dana Farber Cancer Hospital. It is not unreasonable to think that women living only an hour or two away and suffering from breast cancer would visit one or more of these highly respected hospitals for care.
Or that the very sickest women, in general, will travel to Boston for care.

Thus, they claim, the Boston area data might pick up sick women living in the Worcester or Springfield areas also, thus skewing this graph. Maybe…

There are two alternative theories that fail to stand up to critical analysis:

- Some people might suggest that there is 60 – 70% more breast cancer in the Boston female population, due, perhaps, to environmental factors. No data support this proposition. \(^{25}\)

- Others might suggest that the sample size is too small to generate any statistically significant conclusions. This doesn’t stand up as the historical data indicate that these proportional variation trends have existed over a very large population for many years.

The only other potential explanation suggests that Boston area oncologists operate on the same population (from an epidemiologic perspective) more frequently than do Worcester or Springfield area oncologists.

Which analysis is correct? Do women at risk for mastectomies travel from Worcester and Springfield to Boston for care? Or do Boston area oncologists perform mastectomies on patients who would not have this treatment in Worcester and Springfield?

We’ll test both theories by reviewing the leg amputation data and the coronary artery stent data. If we find that the Boston area physicians perform these procedures more frequently than Worcester or Springfield physicians, then we can hypothesize that sick patients travel to Boston for treatment.

But if Worcester or Springfield physicians perform more leg amputations or insert more stents, then we will suspect that local medical treatment preferences are more important. (No one in the Massachusetts medical or medical research community argues that massive numbers of patients travel from Boston to Springfield for tertiary medical care. Also, my casual perusal of the local media over the past 20 years suggests that there are no stories in the local press indicating this trend either.)

\(^{25}\) There is some data to indicate that more rigorous cancer screening identifies more cancer in some regions than in others, but not that there is a significant regional difference in cancer incidence rates. Also, some data indicate that a specific environmental contaminant may affect cancer rates in a very small region, but not in regions as geographically diverse as the three we are considering here.
Leg Amputations

Dartmouth’s raw data indicate the following rates for leg amputations in these three Massachusetts hospital referral regions:

Boston area --- 6.7 per 10,000 Medicare beneficiaries
Springfield area – 10.6 per 10,000
Worcester area – 9.1 per 10,000

Now Boston has the lowest rate of treatment and Springfield the highest.

Regional Treatment Tendencies:  
Leg Amputations  
Source: Dartmouth Atlas. Data downloaded Feb 2011

If you’re seeing this in black and white, Boston is the left bar, Springfield the center bar and Worcester the right bar.

These data show that Springfield area Medicare beneficiaries have about a 60% greater likelihood of having a leg amputated than Boston area beneficiaries.

How can this be?
No one in Greater Boston seriously suggests that Boston area Medicare beneficiaries at risk for leg amputation travel to Springfield for medical care – at least, not in the numbers required to skew these data.

Indeed, those who believed that Medicare females suffering from breast cancer travel from Springfield to Boston, must now believe that Boston folks go to Springfield for orthopedic or vascular treatments. This simply doesn’t make sense. Where would a woman suffering from breast cancer and at risk of a leg amputation go for treatment?

There are virtually no stories in the local press suggesting this migration of people needing leg amputations to Springfield.

It’s beginning to look like the treatment variation argument will prevail.

Inpatient Coronary Angiography

Dartmouth’s raw data indicate the following rates for inpatient coronary angiography in these three Massachusetts hospital referral regions:

- Boston area --- 16.7 per 1,000 Medicare beneficiaries
- Springfield area – 11.9 per 1,000
- Worcester area – 20.4 per 1,000

Now Worcester has the highest rate and Springfield the lowest.

Regional Treatment Tendencies:
Inpatient Coronary Angiography
Source: Dartmouth Atlas. Data downloaded Feb 2011
Again, if you're seeing this in black and white, Boston is on the left, Springfield in the center and Worcester on the right.

These data show that Worcester area Medicare beneficiaries have about a 70% greater likelihood of having a coronary artery stent inserted than Springfield area beneficiaries, and a 22% greater likelihood than Boston area beneficiaries.

Again, there is no evidence of significant underlying population medical differences (remember, all Medical beneficiaries are 65+, and no one suggested that those with coronary conditions move to Worcester, while those with poor leg circulation move to Springfield).

Rather, these three charts suggest quite strongly that the impact of local treatment preferences is quite strong.

Jack Wennberg, the founder of Dartmouth Institute for Health Policy and Clinical Practice, ties all this treatment variation information together. He suggests that treatment protocols vary more based on *medical supply differences and the regional medical culture* than based on *patient medical differences*. He suggests that your chance of having surgery can be predicted by the rate of surgery in your region 10 years prior:
The really fascinating thing to me is to think that what predicts your risk of surgery today in a particular region is what it was ten years ago in the same region. 26

The reason: physicians in a region develop ‘medical cultures’ that get transmitted to new doctors entering the area. Young docs learn from more senior partners in their practice. Career advancement may mean accepting the senior’s approach. After all, what senior partner wants a junior partner who very often disagrees with him?

It seems, from the data presented in this Chapter, that Wennberg is right. Your chances of having a particular medical procedure may vary up to 70% by region in Massachusetts for any one of these three procedures: mastectomy, leg amputation and coronary artery stent insertion.

Extending This Analysis to Other States

Brokers interested in learning about the treatment variation risks in their own state may visit the Dartmouth Atlas website and do their own research.

Here are some of the (astonishing) things they will find:

In Florida, rates of inpatient back surgery vary almost by a factor of 3 by Hospital Referral Region

Back Surgery Rates, Florida
Data from Dartmouth Atlas, downloaded Feb 2011

26 Brownlee, op cit, page 41
These bars are ordered, from left to right, Ft. Myers, Sarasota, Tampa and Miami.

The Medicare populations in these 4 cities are quite similar. Interestingly, Sarasota is about an hour drive from Tampa and Ft Myers. Yet the treatment protocols vary quite significantly.

Why Do These Rate Discrepancies Exist?

The Washington Post ran a series of articles in July, 2005 to celebrate the 50th anniversary of Medicare. One article in the series, *When Geography Influences Care Options*, addressed the issue of treatment variation. 27

Among the Post’s findings:

- The rate of back surgery over the previous 10 years had increased by more than half;
- There is no clear-cut science for treating back pain. ‘Some doctors favor surgery, while others recommend exercise, rehabilitation and other conservative approaches’;

27 Gaul, When Geography Influences Treatment Options, Washington Post, July 24, 2005
• Had Fort Myers's surgeons operated at the more conservative Miami rate, ‘there would have been 4,800 fewer back surgeries from 1992 to 2001 and Medicare would have saved millions of dollars.’

How many millions might Medicare have saved? About 200! That’s 4800 surgeries at an average cost of $40,000, or $192 million.

"It’s highly improbable that Medicare retirees living in Fort Myers prefer back surgery two times as often as residents of Miami," according to James Weinstein, chairman of the Department of Orthopedic Surgery at Dartmouth Medical School. Weinstein has tracked variations in the number of spine surgeries in South Florida for a decade.

Rather than understanding this phenomenon as a function of patient demand, researchers look for ‘surgical signatures’ of physicians. Some back specialists prefer surgery while others prefer medication and therapy. Lacking clear outcome data, the patient is likely to receive the type of care preferred by the specialist.

Unfortunately, clinical preferences are sometimes influenced by economics. The Post notes that back surgery can be very profitable. In 2001, spine surgery accounted for more than half of all profits from orthopedic procedures in hospitals but only 21 percent of the volume, according to a study done for the American Academy of Orthopedic Surgeons.

One hospital chain located in Fort Myers saw its Medicare payments for back surgeries grow by 50% over the previous 5 years.

Are Miami Medicare beneficiaries underserved by back specialists? Do they get an insufficient number of back surgeries? Are they harmed as a result of having fewer back surgeries, per capital, than Fort Myers beneficiaries? There’s no evidence to support any of this.

Instead, Fort Myers Medicare beneficiaries seem to get more back surgeries than necessary, pay more than necessary and possibly put themselves at greater risk of error or infection than their Miami compatriots.

Our underlying ethical question: **do you think your clients would like to know this?**

**********

Mid-Western states have 2+ times more inpatient knee surgeries than some other parts of the country

Inpatient Knee Replacement  
Data from Dartmouth Atlas, downloaded Feb 2011
Again, it appears that the specialist preferences and local medical norms best describes this data. There are no data to suggest that New Jersey, New York or Rhode Island perform too few knee replacements on their Medicare beneficiaries.

Of course, there’s an alternative theory: less healthy mid-western retirees stay in Nebraska, Iowa and Kansas, while healthier retirees move to…New Jersey, New York and Rhode Island? Sorry, doesn’t pass the laugh test.

**Rates of Coronary Artery Bypass Graft exhibit huge discrepancies in next door Hospital Referral Regions**

**Coronary Angiography**
Rates Per 1,000 Medicare Beneficiaries
Data from Dartmouth Atlas, downloaded Feb 2011
These pairs of Hospital Referral Regions border each other:

- Fort Wayne, Indiana borders the Kalamazoo, Michigan region,
- Baton Rouge, Louisiana borders the Metairie, Louisiana region, and
- Asheville, North Carolina borders the Greenville, South Carolina region.

Again, no one claims that Fort Wayne, Baton Rouge or Asheville are underserved by cardiologists. Nor that their populations are sicker than Kalamazoo, Metairie or Greenville.

Rather, it appears that local medical treatment preferences define these variations.

**The Ethical Broker’s Role**

Your clients may find this type of information interesting or useful when considering medical care. Some may prefer more aggressive care – a mastectomy, for example, rather than watching and waiting.

Others may prefer more conservative care – watching and waiting, for example, rather than a mastectomy.
In any case, they may appreciate learning about the treatment tendencies in their area. This may well give them something useful to discuss with their physicians.

Our underlying point here: most patients do not know that these treatment variations exist. The broker who ‘does his fellow a favor’ may help people avoid inappropriate care.

The broker who ‘let’s the buyer beware’ may not be protecting his/her client as well.

Remember also that no regions in the US suffer from insufficient medical care, or widespread undertreatment of patients. The data presented here may suggest that some regions, rather, overtreat patients by providing excessive or unnecessary care.

The broker may have a role in client education and data distribution. By helping to educate the client about systemic risks, the broker may help the client have a more detailed and fruitful discussion with his/her physician.

Brokers who ‘do their fellow a favor’ may aid in this process.

Brokers who ‘let the buyer beware’ probably do not.
Case study: A Discussion with a Benefits Administrator

A Benefits Administrator for a large company puts the company’s benefits out to bid. Two brokers respond. Both offer similar plans at similar prices. Both are experienced. Both are professional. Both offer all the standard services – 401(k) administration, FSA administration, wellness programs, etc.

The Benefits Administrator tries to find some reason to choose one broker over the other. Since they appear to be mirror images of each other, he has little to choose. So he asks both brokers ‘why should I choose you?’

Broker A talks about experience: 20 years in the business, a good customer service reputation, intimate knowledge of carriers and plenty of references. Broker A talks about his commitment to clients and interest in helping clients. He even offers to meet with the Benefits Administrator quarterly to provide policy and regulatory updates.

Certainly, thinks the Benefits Administrator, Broker A is fine. There’s nothing wrong with him.

Then Broker B comes along. This broker also has years of experience, a good customer service reputation, good relations with the various local insurance carriers and plenty of references. This broker also offers to meet quarterly to discuss policy and regulatory updates. (Both brokers, it seems, value face time with the Benefits Administrator.)

But in addition to all these services, Broker B makes a surprising statement:

My company has a clear business standard that defines our relationship with clients. The ethical standard that we embrace is called ‘Do Your Fellow A Favor’. I’ve studied business ethics and decided that I want my company and my employees to live up to this standard.

Many of my competitors use a different ethical standard. They ‘let the buyer beware.’

Intrigued, the Benefits Administrator asks Broker B to continue.

I won’t save you any premium money in the short term as compared to Broker A. He’s a fine broker who is perfectly capable of running rates and showing alternative policies.

I won’t show you any plans that he doesn’t. And I offer all the same services as he does.
But in addition to offering everything that he offers, under my ‘do your fellow a favor’ standard, I’ll also educate your employees about how to use our healthcare system.

I’ll tell them things about the healthcare system that they probably won’t learn from their doctors but that may help them interact with their doctors. I’ll help them become wiser consumers of medical care.

The Benefits Administrator was starting to yawn as Broker B continued:

Better educated consumers, who shop more wisely, use medical resources more efficiently. In the long run, this may save you money….maybe quite a bit.

The Benefits Administrator suddenly perked up:

You’ll save us money? Explain. Give me an example.

Broker B then summarizes:

We know, for example, that the rate of Caesarian births varies among hospitals in this state almost 3 to 1. The infant mortality rates and maternal mortality rates, though, are about the same among all in-state hospitals. 28

Researchers have not identified any significant health differences among women delivering at the various hospitals. Instead, they found that the main causes for this Caesarian birth rate variation are hospital staffing and organizational differences, not patient epidemiological differences.

This means that the same woman will more likely have a Caesarian at some hospitals than at others. Her choice of hospital may have an impact on her likelihood of having a Caesarian delivery.

‘I didn’t know that’ exclaims the Benefits Administrator. Broker B continues:

I have no opinion about whether Caesarian births are better or worse than natural births. But some of your employees might. They may find this information useful when planning their delivery.

At the very least, it may give them something to talk with their obstetrician about.

28 This discussion uses real data from Massachusetts hospitals. See Boston Globe, Why Caesarian Birth Rates Differ at Area Hospitals, 6/7/2010, Cooney
‘So,’ suggests the Benefits Administrator, ‘having this information available may reduce my employee’s rate of unintended Caesarian deliveries. That could affect our Experience Modifier and save us some premium money in the future. Interesting.’

Broker B continues:

_Here’s another example of what we discuss with employees. It’s an analysis of the rate of angioplasty procedures performed in Smithville and Jonesville, the two largest cities near here._29

_People in Smithville have about 3x the rate of angioplasties as people in Jonesville, and about 4x the national average. Researchers have not discovered any major epidemiological differences among people in the two towns._

The Benefits Administrator: ‘Why are there such stark differences?’

Broker B:

_I don’t know for sure, but it seems that the physicians in Smithville favor angioplasties in cases where the physicians in Jonesville would not. The researchers seem to suggest that the Smithville physicians use angioplasty more aggressively than the Jonesville physicians._

Benefits Administrator: Why is that?

Broker B:

_Again I don’t know for sure, but it seems that studies of the usefulness of angioplasty present a confusing picture. Some studies show that angioplasty is a useful and necessary procedure that helps a great number of people. Other studies indicate that it is useful in only a much smaller number of circumstances._

_Some physician groups embrace this treatment protocol and use it widely; others seem to shy away from it._

‘Interesting,’ comments the Benefits Administrator. ‘That seems to suggest that our employees living in Smithville will have higher rates of this procedure than our employees living in Jonesville. Let me check my claims data and get back to you.’

---

29 I have changed the town names, but use actual data as presented in the New York Times, Heart Procedures is Off the Charts, 8/18/2006
The Administrator, who has a remarkably good computer system, immediately compares claims data and, sure enough, notes this discrepancy. 'I wonder how many Smithville angioplasties would not have been performed on Jonesville residents. I wonder what the cost differences would be.'

Broker B continues:

_I do not know whether angioplasty is a good treatment protocol or not; I'm not a doctor. I can't give medical advice or opinions. Neither can you._

_But your employees in Smithville and Jonesville might be interested to see this data. We can present it to them. It may help them discuss their treatment options with their own physicians._

The Benefits Administrator then pauses and thinks for a couple of minutes. ‘Giving us data like this is a good thing. But it may be too specific for many of my employees. They may not need Caesarian or coronary treatment information. But they may need information about other treatments. What can you do for us there?’

Broker B responds:

_We provide general information about our healthcare system, for example, about 'treatment variation' – like the data I just presented. We explain what it is, why it exists and how your employees can learn more. We use local examples for medical procedures ranging from mastectomies to leg amputations to back surgeries._

_We want to help your employees become sophisticated healthcare consumers. We want to provide them with data to discuss with their physicians._

_We never advise people whether or not to seek treatment._

_Instead we teach them how our healthcare system works. We try to give them tools to negotiate the system better, and to protect their own interests better._

_In short, we inform them of systemic problems that they may not have realized exist._

In the end, the Benefits Administrator considers the two brokers. One who takes the 'let the buyer beware' approach about dealing with our healthcare system. The other who 'does his fellow a favor'. Which will help my employees the most, he wonders.

In the end, the Benefits Administrator chooses….. _Well, who would you choose?_
If the Broker ‘let’s the buyer beware’, then who will ‘do his clients a favor’?

In the 1990s, carriers restricted access to medical care as part of their cost containment programs. Patients needed referrals – which were not always accepted by the carrier. Carriers limited access to expensive specialists, limited the number of physician visits / condition, or limited the types of medications covered.

The American public perceived this as an attempt to improve carriers’ financial positions rather than to improve patient outcomes – and objected to these inappropriate restrictions.

One result: today’s insurance policies allow easier, even unfettered (in the case of many PPO or POS type plans – the ‘generous insurance plans’ described by Mr. Rosof in our Preface) access to the hospital or specialist of choice. Post-2000, many carriers have acquiesced to consumer demands for easier access to care. Today many insured Americans can get access to all the medical care available.

Is this always a good thing? Not necessarily, suggests Mr. Rosof in our Introduction.

Purchasing medical services is different from purchasing most other services: The Impact of Trust

John Wennberg, from Dartmouth, addresses the underlying issue here. Purchasing medical services, he suggests, is vastly different from purchasing goods and services in most markets. ‘The doctor-patient relationship is different,’ he suggests ‘because of the asymmetry of information.’

The consumer – your client:

Does not know what he or she truly needs; it is the physician who knows the nature of the patient’s illness and can select the right treatment…[as a result] patients delegate decision making to the seller of the services. 30

Arnold Relman, Professor Emeritus of the Harvard School of Public Health, echoes Wennberg on the asymmetry of medical information between patient and physician: 31

Patients usually know much less about the diagnosis and treatment of their disease or injury than their doctors do. Furthermore, because of illness or injury they may be in no condition to evaluate their options.

30 Wennberg, Tracking Medicine, page 23
As a consequence they cannot independently decide what medical services they want in the same way consumers choose services in the usual market...

The penalties for making a mistake in the health care market are usually higher than in others.

Patients must therefore trust their physicians to decide what services they need.

Imagine doing this with your home repair contractor. We might call it ‘license to steal’ if the homeowner said ‘tell me what I need and I'll buy it all.’

But in medicine we accept that the service seller (physician) will identify the problem, design the solution, implement the solution, get paid for his/her efforts and that the patient will agree.

Various factors may affect advice, consciously or subconsciously

Dartmouth’s Wennberg provides a cautionary note.

Physician decisions...are strongly influenced by the capacity of the local medical market - the per capita number of...medical specialists, and hospital or ICU beds, for example. 32

In other words, physicians in areas with greater medical services available are likely to design more expensive and more generous treatment programs than physicians in areas with fewer medical services available...for the same patient. And often generating the same outcomes.

(Remember that in the US, no regions have insufficient medical resources as, for example, do many foreign countries. This is, in part, due to Medicare’s payment system. We do not have significant regional mortality rate differences that researchers attribute to a lack of medical resources. All US regions have at least a sufficient level of medical resources available.)

Here is Wennberg’s startling suggestion: treatment protocols vary more based on medical supply differences and the regional medical culture than based on patient medical differences. He suggests that your chance of having surgery can be predicted by the rate of surgery in your region 10 years prior:

32 Ibid. page 11
The really fascinating thing to me is to think that what predicts your risk of surgery today in a particular region is what it was ten years ago in the same region. \(^{33}\)

As a result, a Medicare beneficiary moving from Tampa Florida to Fort Myers Florida – about 2 hours away - increases his/her chance of receiving back surgery by 60%. \(^{34}\)

Or residents of Elyria, Ohio are about 3 times more likely to have an angioplasty procedure than are residents of Cleveland, about 20 miles away. \(^{35}\)

An Embarrassing Live Example

Wennberg and his colleagues at Dartmouth Medical School tested this Treatment Variation idea on physicians practicing in Boston and New Haven. \(^{36}\)

Their reasoning: the Boston medical landscape is dominated by Harvard Medical School, its affiliated teaching hospitals and its alumni. The New Haven medical landscape is similarly dominated by Yale Medical School. Both are outstanding and prestigious academic medical centers. Both publish widely. Both read each other's research studies.

We would expect both to treat similar patients similarly. Wennberg wanted to explore this idea, and determine if the supply of medical resources affected the physician’s judgement.

Here’s what Wennberg’s team did. First, they counted the number of hospital beds available in the Boston and New Haven areas. They then divided the number of beds by the number of Medicare beneficiaries to get a ratio. (They used Medicare beneficiaries because Medicare provides sufficient data for this research study.)

Boston had 55% more beds per 1000 Medicare beneficiaries than did New Haven. And, just as Roemer had predicted in his Law some 25 years earlier, Boston area Medicare beneficiaries spent about 40% more time in the hospital than did New Haven beneficiaries.

\(^{33}\) Brownlee, op cit, page 41

\(^{34}\) Ibid.

\(^{35}\) Heart Procedure is Off the Charts, NY Times, 8/18/2006

\(^{36}\) This story comes from Brownlee, Overtreated, pages 111 - 112
This meant that a patient in Boston had a much higher likelihood of being hospitalized for something that a similar patient in New Haven would not be hospitalized for!

Yet, as Shannon Brownlee, another Dartmouth scholar, summarized the situation:

Patients in Boston weren’t any sicker than those in New Haven; they were just more likely to be hospitalized – and admitting them more often to Boston hospitals did not appear to improve their outcomes.

Wennberg’s initial publication of this phenomenon was entitled ‘Are Hospital Services Rationed in New Haven or Over-Utilized in Boston?’

He continued his research. He discussed standard admission decisions with physicians in Boston and New Haven. He asked physicians in New Haven if they felt like they were forced to ration care, and they said no. He asked physicians in Boston the same question, and got the same answer. Physicians in both cities felt that they had sufficient medical resources available and hospitalized patients at the right rate.

He then presented his findings to physician groups in Boston and New Haven. But he played a trick: he reversed the labels on his slides!

He labeled Boston admission rates ‘New Haven’ and labeled New Haven as ‘Boston’. He then showed Boston area physicians that ‘New Haven’ doctors (i.e., themselves in reality) were admitting patients 40% more often. And he showed New Haven doctors that ‘Boston’ physicians were admitting 40% less.

He then asked the Boston group to comment on how New Haven docs practiced medicine. The result, according to Megan McAndrew, editor of The Dartmouth Atlas: The Boston audiences

Would come up with all these reasons why those guys down in New Haven were admitting too many patients.

This group, being highly trained physicians, would explain in detail which admission errors the New Haven docs made – by disease type, etc. Wennberg dutifully wrote everything down.

He then said ‘Opps, I mislabeled the slides’ showed the correctly labeled slides and went through the reasons given for poor admission decisions in New Haven. He discussed item-by-item the treatment differences and hospital admission differences, by patient presentation and disease, for Boston and New Haven.

37 Lancet, 1987
The lesson here, according to Brownlee:

*Doctors were blithely, astonishingly unaware that the supply of hospital beds was affecting their clinical decisions. They thought they were putting patients in the hospital entirely on the basis of what would help the patients…*

Not based on any external supply factors.

I have no idea whether Boston admission rates or New Haven admission rates were correct. I only know that they differ. As a consumer, I would like someone to inform me of this discrepancy.

Our ethical question returns: *do you think your clients should be advised of this information? Would you like to be advised of this if you were a client? If so, how would you know that this information exists? Who, in our healthcare system, would tell you?*

**How Much Consumer Education?**

The average doctor’s visit only lasts about 8 minutes. 38 During this time, the physician needs to diagnose the patient’s problems, describe the treatment options and help the patient make a decision – that’s plenty to do in 8 minutes.

The physician doesn’t also have time to (a) explain the treatment variation issues, (b) research the likelihood of excess care for a particular medical problem in a specific region, (c) research the treatment tendencies of each hospital in the region for that particular medical problem (see our example, above, of Caesarean deliveries by hospital) and (d) answer all the patients questions. That’s too much information for the poor patient – who may be emotionally upset by the diagnosis in the first place!

Our physician, thus, is unlikely to ‘do your clients a favor’ during the short office visit…even if the physician understands the treatment variation issues.

But even worse, from a patient education point of view, our medical system does not pay anyone to disagree with the physician

By analogy, our legal system requires both a prosecution and defense attorney to question witnesses. That way neither has too much power.

In our medical system, however, patients only get one point of view ---from providers who earn money by providing care. Your doctor plays the equivalent roles of police

---

38 Estimate from David Cordani, CEO of Cigna at Keynote Lecture, Yale Healthcare Conference 2015
investigator, prosecutor, defense attorney and judge. This puts enormous advisory power in the hands of one person – and, interestingly, a person who has an economic interest in the patient’s decision.

Our system does not pay anyone to oppose the provider’s point of view.

Carriers might also play that role – but the managed care experience of the 1990s has turned popular opinion against trusting carriers too much.

Second opinions might fulfill the role…but probably do not. Physicians in the same group practice, hospital or region tend to treat patients with similar protocols, and disagree far less than perhaps they should. This is very well documented in the healthcare literature.

Also, physicians may have informal – perhaps even unconscious – motivations to support each other.

No one, it seems, will do your clients a favor….except you, the broker!
How Should an Ethical Broker Proceed?

In this concluding chapter we’d like to offer some general advice for how best to do your fellow a favor. \(^{39}\)

1. Educate yourself about our healthcare system.

   The ethical broker has a responsibility to ‘do your fellow a favor’. The more you know about our healthcare system, the better you can educate your clients.

   Today’s bookstores are full of insightful and useful books about healthcare. Some that we have found particularly useful (also quite engaging and easy to read):

   - *Overtreated*, by Shannon Brownlee;
   - *Complications*, by Dr. Atul Gawande;
   - *Better*, by Dr. Atul Gawande;
   - *Best Care Anywhere*, by Phillip Longman;
   - *Should I Be Tested for Cancer?*, by Dr. H. Gilbert Welch;
   - *Overdiagnosed*, by Dr. H. Gilbert Welch;
   - *Know Your Chances*, by Dr. Steven Woloshin, et al
   - *Tracking Medicine*, by Dr. John Wennberg

   Here’s typical feedback from our students who have read these books: they contain fascinating and very useful information. Ethical brokers use that information in their normal professional work.

2. Help your clients ask questions.

   Patients sometimes are intimidated by specialists; sometimes awed by specialists; or sometimes tongue-tied in front of specialists. The better you educate your clients about the inner workings of our healthcare system, the better they’ll be able to ask important questions of their physicians.

3. Give general, but not client specific advice. Do not play the role of doctor or give medical advice. This is illegal unless you are licensed to practice medicine.

   Rather than give specific, detailed advice to a client about his / her specific medical condition, we encourage you to offer general education about the workings of our system.

---

\(^{39}\) Some of this advice comes from the Afterward of Overtreated. See Brownlee, op cit pages 308 - 310
You can, for example, use the Dartmouth Atlas of Healthcare (www.dartmouthatlas.org) to see comparisons between your region / state and other states or national averages.

Some other useful websites include the Kaiser Family Foundation site (www.KFF.org), the Centers for Disease Control site (www.cdc.gov) and the Agency for Healthcare Research and Quality site (www.ahrq.gov) and the Commonwealth Fund (www.commonwealthfund.org).

Another very useful website is www.TheMedicalGuide.net that teaches consumers how to avoid unnecessary medical care.

These sites provide extensive data about the operation of our healthcare system.

**Conclusion**

In this course, we have suggested that ethical brokers educate their clients. An ethical broker adopts the ‘do your fellow a favor’ standard rather than ‘let the buyer beware’.

In this Conclusion, though, I would like to extend this idea, and suggest that adopting the ethical standard of ‘do your fellow a favor’ is good customer service. The more you treat your clients as you would like them to treat you (were conditions reversed), the more satisfied they will be with your service.

‘Customer service’ in this regard is much more than answering telephones promptly, responding to emails and processing the myriad of forms that health insurance brokers process. It is also more than generating quotes for health, life, disability and dental coverage.

Customer service begins to mean ‘help your customers navigate our healthcare system.’ This may be far more important than answering phones promptly.

Imagine how satisfied a client will be with your service when she learns from you about the risk of Caesarian births at local hospitals. Absent that knowledge, she might have had an (unwanted) Caesarian; her lack of information may have reduced her ability to plan and increased her risk of a procedure that she did not want. Armed with information, however, she can make more informed decisions about where and how to deliver her baby.

Alternatively, imagine how pleased a different woman may be to learn that some hospitals perform very low rates of (desired) Caesarian births. She may use your information in discussions with her obstetrician, and alter her choice of delivery hospital as a result.
Imagine how satisfied another client will be when they begin a conversation with their cardiologist armed with data about the relative rates of angioplasty performed in your region compared to the national average.

Now ask yourself the chance that a client who is so satisfied with your services will switch to another broker at the next policy renewal. I suggest that your client retention rates will increase as you embrace the 'do your fellow a favor' ethical standard.

Good ethics is good customer service.

We have an ethical tradition of full disclosure and ‘do your fellow a favor’ extending back to the time of Abraham. I hope that today’s health insurance brokers will embrace this tradition, and practice both good ethical behavior and good customer service as a result.
Case study: some health insurance trends since 2000.
Did the health insurance industry act ethically?

This section was originally published as Chapter 2 of my book Transparency Metrics. I have edited it slightly and include it here to present some systemic development issues in an ethical context. Gary Fradin

This section will describe two major industry activities post-2000s: the introduction of Consumer Driven Healthcare aimed at controlling costs and of HEDIS quality measures aimed at improving quality. These are not the only programs developed. Rather, they are examples of the types of programs implemented by carriers over the past decade. As you read this, consider whether the insurance industry acted ethically (in our terms) or not. Did it let the buyer beware or do your fellow a favor? What responsibilities does this place on the broker’s shoulders?

Our starting point: the 2004 NCQA report

The National Council on Quality Assurance, a managed care industry association, published the following in its 2004 Annual Report, clearly identifying the need to improve the quality of our nation’s medical care. I choose 2004 because it was the first year after the introduction of Health Savings Accounts in the Medicare Modernization Act of 2003 and because the 2004 NCQA report so eloquently framed these issues: The disparity between the care most Americans receive and the care delivered through the nation’s best plans results in from 42,000 to 79,000 premature deaths each year……thousands of preventable second heart attacks, kidney failures and other conditions…..more than $9 billion in lost productivity and nearly $2 billion in hospital costs could be averted through more consistent delivery of best-practice care……more than 14,000 heart attacks and strokes could be prevented each year through better diabetes management alone.

This report followed on the groundbreaking 1999 To Err is Human study by the Institute of Medicine that documented, for example: preventable medical errors cost the US economy between $17 billion and $29 billion annually plus thousands of preventable annual deaths…These errors include diagnostic, treatment, preventive and systemic problems…The IOM believes that faulty systems, processes and conditions, rather than individual physician mistakes cause these medical errors. These preventable errors account for up to about 100,000 unnecessary deaths per year.

Both statements describe a poor quality medical care system that includes huge amounts of unnecessary care, expense, preventable injury and death, all of which has a significant financial impact. How did the insurance industry respond to these types of wake-up calls? In part by introducing process metrics like the HEDIS system that I’ll describe later, and in part by introducing Health Savings Accounts, a tax codification of the trend toward high deductible health plans, the so-called Consumer Driven Healthcare, aimed at controlling medical care inflation.

Consumer Driven Healthcare
Consumer Driven Health Care aims to treat medical care purchasing like all other consumer purchases such as cars and homes. It does this by requiring consumers to spend their own money on medical care, up to some specified annual deductible.

Consumer engagement starts – and generally stops – with deductibles. Few plans include meaningful medical care quality metrics like the Number Needed to Treat or Number Needed for Harm. Few consumers know their Starting Risk of developing various medical problems, or the Modified Risk offered by medications, therapies or tests. Even fewer can understand which medical claims - from medical ads for example - are meaningful and which are not. The industry has, so far at least, failed to teach consumers how to choose high quality medical care over low and avoid unnecessary care altogether.

Lacking this knowledge, consumers spend their money unwisely on medical waste…up to, about, 1/3 of the time…regardless their deductible or the tax treatment thereof. What price-based medical decision making overlooks: **better outcomes almost always cost less than poorer ones.**

One reason for this: better medical quality leads to fewer missed diagnoses, hospital readmissions, unnecessary tests and unnecessary procedures. This suggests that wiser medical consumers – i.e., those who make the most well-informed medical care quality decisions – are generally the *lowest cost* medical consumers, not the ‘penny-wise, pound foolish’ folks who shop based on price.

Dissuading people from choosing *quality* care by motivating them to choose *cheaper* care may well take us in the wrong direction. Medical care prices are, of course, important. Pricing information is *most appropriate* for medical commodities like radiologic scans, pharmaceutical products, and routine tests and procedures. In these, the care quality is either approximately the same - many hospitals use the same type of MRI machine, for example - or unknowable. How can a patient determine the quality of one physical therapist as compared to another? They can generally only determine the friendliness.

Pricing information is *least appropriate* for complex, expensive, highly individualized, potentially life threatening medical interventions. Would an elderly patient suffering from congestive heart failure, decreased kidney function, Parkinson’s disease and diabetes - who needs his pacemaker removed and upgraded - choose the least expensive facility? Or an obese, diabetic woman suffering from COPD and lupus choose the least expensive facility for her double mastectomy? I suspect these people would want the *best* facility because the risks are so high. These individualized, non-routine interventions are the ones with the most potential to save money. But they’re the ones for which we’re least able to get meaningful pricing information.

In general, price is a secondary consideration in medicine, one that wise patients should only consider after they have determined the care quality.

Here’s how the wise patient would make an informed medical decision, at least conceptually: First, decide which medical care *treatment* offers the best outcomes for people like you. Spinal fusion surgery or back therapy, for example; mastectomy or watchful waiting. Second, decide which *hospitals and physicians* provide that treatment the best, as measured by outcomes for people like you, Third, if you find two hospitals or physicians that generate the same outcomes for the same treatment, then sure, choose the least expensive.

Of course, medical decisions are often rushed so you can’t go through this sequence in detail. Often these data don’t exist for your particular medical need so you need to estimate. But the key point remains:
choose high quality, necessary medical care based on outcomes for people like you as a first consideration, and relegate cost issues to a secondary role. So-called Consumer Driven Healthcare tends to flip this process on its head.

**Consumer Driven Healthcare Defined by Deductibles (largely)**

In common insurance lingo 'consumer driven products' are those with $1000 or more annual deductibles. Each consumer spends that $1000 as best he/she sees fit – for physician visits, medications, tests or therapies. Only after satisfying the deductible does insurance begin to pay. Then, depending on the specific plan design, insurance pays all of the additional medical expenses, or part up to some set amount.

In theory, when people spend their own money they shop more wisely and get better value than they would if they only spent the carrier's money. This is the same theory that underlies other consumer products, ranging from refrigerators to cars to tennis racquets. Unfortunately, the theory fails in healthcare due primarily to the lack of medical quality information – the necessary first step to wise medical care decision making. Today we only have some medical pricing information. (I'll give examples shortly.)

The lack of quality info makes medical decisions different from, say, car purchasing decisions. The car buyer can compare various cars before deciding which to purchase. Large or small, good gas mileage or poor, lots of luxuries or few, good crash-testing rating or not, high resale value or low, built-in GPS units, etc…and price too, of course! But the medical purchaser generally has very little similar information. How effective is this intervention compared to that? Or this medication compared to that one? Which doctor has the best outcomes for people with my illness? Which hospital? You don't need a medical degree to compare the effectiveness of different medical treatments. You just need the information. But we generally lack it.

For this reason, I suggest that today's so-called Consumer Driven Health Care is really nothing more than cost shifting to sick people. These plans have virtually nothing to do with consumerism. And they can't, since patients have virtually no useful medical care quality information today upon which to make wise medical care decisions.

**Some Examples**

To help patients spend their deductibles wisely, insurance carriers, private companies and some states have developed and promoted pricing tools – lists of medical treatment prices from various local providers that, theoretically, help patients shop for the best deal. Some of these models are extremely detailed, showing, for example, what an individual consumer will pay based on his/her deductible payments so far this year, how much your employer will pay, what types of follow up care you may need and what they will cost, etc.

I'll show you some simple examples. To avoid any confidentiality or related issues, I'll use a public pricing site, the New Hampshire state site, nhhealthcost.org. I chose it because it was easy to use. It may or may not be representative of medical prices nationally, but it serves to show how different providers charge
vastly different amounts for the same medical services.\textsuperscript{40} The first chart shows sample total costs (deductible + insurance payment) for arthroscopic knee surgery. Note the huge price difference among providers: \textsuperscript{41}

<table>
<thead>
<tr>
<th>Facility</th>
<th>Total Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concord Ambulatory Surgery Center</td>
<td>$3,431</td>
</tr>
<tr>
<td>Franklin Regional Hospital</td>
<td>$5,118</td>
</tr>
<tr>
<td>Cheshire Medical Center</td>
<td>$6,644</td>
</tr>
<tr>
<td>Parkland Medical Center</td>
<td>$7,717</td>
</tr>
<tr>
<td>Weeks Medical Center</td>
<td>$9,873</td>
</tr>
</tbody>
</table>

We have no quality information – infection rates, speed of return to normal health, patient satisfaction, 30 day readmission rates, etc. Nor do we know for which patients this is necessary surgery and for which unnecessary. But we know that prices for this procedure range from $3431 to $9873. Radiology prices also vary hugely. Here are sample prices for a pelvis MRI, same subscriber, downloaded the same day:

<table>
<thead>
<tr>
<th>Facility</th>
<th>Total Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derry Imaging Center</td>
<td>$1,486</td>
</tr>
<tr>
<td>St Joseph Hospital</td>
<td>$2,574</td>
</tr>
<tr>
<td>Exeter Hospital</td>
<td>$2,758</td>
</tr>
<tr>
<td>Speare Memorial Hospital</td>
<td>$3,381</td>
</tr>
<tr>
<td>Monadnock Community Hospital</td>
<td>$3,868</td>
</tr>
</tbody>
</table>

\textsuperscript{40} I downloaded all this information on December 6, 2012, posing as an Anthem subscriber with HMO coverage. Anthem was one of the carrier options and HMO one of the plan options. I chose both at random.

\textsuperscript{41} http://www.nhhealthcost.org/insuredWizardUserInput.aspx?procedure=2&procedureName=Arthroscopic+Knee+Surgery+(outpatient)
Again, no quality information – rates of false positives, misdiagnoses, overdiagnoses etc. No information on number of call backs, unnecessary further investigations, etc. And no indication of the number of unnecessary pelvic MRIs performed. But an impressive price discrepancy. Some patients – presumably – will choose the lower cost provider to save money. Others may choose the higher priced treatments, assuming that the most expensive is the best. Still others may choose the one closest to home, regardless the price, especially if they have already satisfied their deductible. And others may follow their doctor’s advice, regardless of price. I’m not sure what all this has to do with medical care quality – the ‘up to about a third generating no detectable benefit’ – as we have no reliable, similarly detailed outcome metrics to combine with these prices. I’m also not sure exactly how consumers will change their behavior when faced with this pricing information. But some industry folks are developing ways to address that behavioral issue.

**New plan designs: let the buyer beware of details?**

Once prices for lots of procedures – and for bundles of procedures – become available, carriers and brokers can design reference based pricing plans. That’s likely the next new thing. Reference based pricing takes the deductible concept a step further: The deductible applies to all your medical care. Once you pay it, the care is free for the rest of the year, though some plans may still call for a co-insurance payment up to some specified amount. Reference based pricing says the insurer will only pay the lowest price in the region after you satisfy your deductible. The insurance subscriber is responsible for all or part of any excess if he/she chooses a different provider.

The low price provider may change by treatment. In our examples above, Derry was the low price pelvis MRI provider and Concord the low price arthroscopic knee surgery vendor. Whichever provider is the lowest price becomes the ‘reference’ for that treatment. These plans are still very new and we don’t have evidence of their effectiveness. Creative carriers and brokers will almost certainly develop variations on this theme.

Prices serve a variety of supplier goals including profit generation and customer attraction (marketing). I’ll use an automotive analogy to introduce all this and then show how hospitals do the same things.

Here’s the example: An independent auto mechanic advertises oil changes for $19.95. Meanwhile the large dealer up the road charges $34.95. Is the independent better or worse at oil changes? We don’t know. But by charging $19.95 he’s probably trying to attract new customers who will like his work and use his services for brake jobs, tune-ups and other higher priced, more profitable work. In other words, the $19.95 oil change is part of his marketing strategy to get people in the door with the low priced item and then upsell them: ‘You know, your brake pads are pretty thin. I could replace them while I do your oil change.’

Retailers do this all the time: attract new customers with cheap, low margin items and then sell them higher priced expensive stuff.

Two points here: First: there are lots of auto repair competitors, so consumers can quite easily research their options. You can’t make too much of an auto repair mistake as you’re normally only spending a few hundred dollars at most. A bad decision probably just means you overspend by a bit. Pretty small risk to the consumer. Not so true of complex medical issues where poor quality care can literally kill you.
Second, auto repairers are notorious for upselling unnecessary services, at least in the common public perception, so consumers are ‘defensive shoppers,’ constantly on their guard to avoid getting ripped off. George Castanza articulated this in a 1995 Seinfeld episode, describing his dealings with an auto repair facility: 42 Well of course they’re trying to screw you! What do you think? That’s what they do. They can make up anything: nobody knows! “Why, well you need a new Johnson rod in here.” Oh, a Johnson rod. Yeah, well better put one of those on!

Could hospitals do the same thing, upsell patients? Attract them in and then provide lots of additional, perhaps unnecessary but high margin billable services?

Item: Emergency room physicians at Carlisle Regional Medical Center in Pennsylvania had targets for how many patients to admit. According to the New York Times investigation, published in November, 2012: 43 doctors said that hospital administrators created targets for how many patients they should admit. More admissions translated into more dollars for the hospital…one of the physicians recalled getting phone calls in the middle of the night questioning why he had not admitted an older patient whose hospitalization he could easily have justified. “The pressure to admit was so high,” he said.

Item: 60 Minutes reported on December 2, 2012 that Health Management Associates, the 4th largest for-profit hospital chain in the country relentlessly pressured its doctors to admit more and more patients -- regardless of medical need -- in order to increase revenues. 44 The Emergency Room admission benchmark was 15% in some places, 20% in others and 50% for Medicare enrollees, with hospital administrators emailing ER docs messages like: Only 14 admits so far!!! Act accordingly… I have been told to replace you if your [admission] numbers do not improve. Sounds like upselling to me. ER is a low margin business, like oil changes. Inpatient admissions - far more profitable. Like Johnson rods.

Just image the potential impact if hospitals compete with each other on advertised prices, but compensate their doctors based on admission rates or surgeries performed.

Item: On September 12, 2012, Westerly Hospital in Westerly, Rhode Island offered free PSA screening from 5 – 6 PM. 45 ‘Free’ is the ultimate low cost. Now…why would a hospital give its services away for free? And why PSA screening in September 2012, four months after the US Preventive Services Task Force recommended against PSA screening for prostate cancer?

Dr. Otis Brawley, Chief Scientific and Medical Officer at the American Cancer Society suggested an answer in an interview: 46 We at Emory have figured out that if we screen 1,000 men at the North Lake

42 http://www.imdb.com/title/tt0697702/quotes


44 60 Minutes, Hospitals: The Cost of Admission, December 2, 2012

45 http://www.westerlyhospital.org/hospital-offers-free-psa-screening-on-sept-12/

46 http://www.whale.to/cancer/psa_screening.html . Brawley reports a similar story in his book How We Do Harm, pages 228 - 9
Mall this coming Saturday, we could bill Medicare and insurance companies for $4.9 million in health care costs [for biopsies, tests, prostatectomies, etc]. But the real money comes later--from the medical care the wife will get in the next three years because Emory cares about her man, and from the money we get when he comes to Emory's emergency room when he gets chest pain because we screened him three years ago. Questioner: You're saying that screening creates long-term customers. So, did Emory Healthcare decide to go ahead with the free PSA screening on Saturday?

Dr. Brawley: No, we don't screen any more at Emory, once I became head of Cancer Control. It bothered me, though, that my P.R. and money people could tell me how much money we would make off screening, but nobody could tell me if we could save one life. As a matter of fact, we could have estimated how many men we would render impotent...but we didn't. It's a huge ethical issue.

Seems that Westerly Hospital made a different decision.

I’m left to wonder if publishing price lists will still leave as unnecessary about half the Connecticut mastectomies...or perhaps increase the rate of unnecessary mastectomies if radiologists are compensated based on mastectomy rates or a similar metric.

I just don’t see how all this pricing information cuts down on our rate of unnecessary care or switches people from low to high quality treatments. I do see how this can cut some hospital and treatment costs, but I hesitate to guess whether this means better care or worse. Will hospitals routinely admit more patients in the 'gray area' between definitely needing admission and definitely not to maintain their income...like our ER examples above? Will others do more investigations to find more microscopic abnormalities that require more low quality care, perhaps like Westerly Hospital? Will our overall medical inflation rate actually rise? Shopping for medical care based on price requires people to understand what those prices actually mean. I'm not sure many do. I worry about the tyranny of the unintended consequence.

**Spurious disclosure metrics: ethical or not?**

Here are some New Hampshire mammography prices. As you review these, remember Dr. Brawley’s comments and ask yourself ‘if I ran a high priced hospital, how could I keep my mammography prices high to maintain my income while also maintaining my volume?’ I probably wouldn't want to compete on mammography price as that could mean foregoing $300 or more per mammogram with a potentially significant negative impact on my bottom line. ($300 per mammogram, 11 mammograms/day, 6 days/week is about a million dollars per year.)

<table>
<thead>
<tr>
<th>Facility</th>
<th>Total Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>St Joseph Hospital</td>
<td>$273</td>
</tr>
<tr>
<td>Woman's Life Imaging</td>
<td>$291</td>
</tr>
<tr>
<td>Elliott Hospital</td>
<td>$313</td>
</tr>
</tbody>
</table>

- 65 -
One suggestion (I’m sure creative hospital marketing people will come up with dozens more): a hospital might decide to attract mammography patients by advertising an ‘over 95% 5 year breast cancer survival rate’.

That sounds pretty good. People might pay more to use this facility based on the quality it apparently has and the peace of mind it offers. It’s a good marketing campaign that might even increase patient volumes while the hospital maintains high prices. But the 95% 5 year survival rate tells nothing about the hospital’s breast cancer treatment quality; survival rate statistics are spurious, misleading at best and bogus at worst.

Here’s why: The 5 year survival clock starts when the breast cancer is diagnosed. Over time, we have diagnosed smaller and smaller abnormalities, earlier and earlier in the breast cancer’s life. In fact, between the mid 1990s and mid 2000s, we diagnosed breast cancer about 1 full year earlier, according to the National Cancer Center’s SEER data.

Average age of breast cancer diagnosis mid-1990s: about 62; 47
Average age of breast cancer diagnosis 2006: about 61. 48

Unfortunately, the average age of breast cancer death was the same in 1996 and 2006: 68. 49

Screening starts the 5 year clock earlier. Screening identifies an abnormality before it becomes symptomatic. It may take a year, 2 years, 5 years or more to become symptomatic, if ever. Identifying an abnormality – breast cancer, for example – by screening automatically adds all the pre-symptomatic time to the survival time. This increases 5 year survival rates at even poor quality hospitals, because most of the women diagnosed wouldn’t die within 5 years anyway.

Diagnosing more women with small, young, hard to detect cancers will increase your 5 year survival rate - by definition - regardless of your medical care quality. You can, thus, improve your 5 year survival rates (or 10 or 20 year rates) by diagnosing cancer earlier but without treating it better or without extending the woman’s life at all. Women may still die at the same age, but just live longer with the (earlier) cancer diagnosis. This is apparently the case in the US, or diagnosing cancer no earlier, but providing better cancer treatment and extending the woman’s life through better care, or both. Knowing only the 5 year survival rate doesn’t tell us which of these 3 situations occurred. That’s why 5 year (or 10 year, or any

47 Glockler, Cancer survival and incidence, The Oncologist, December 2003


number of year) survival rates may not tell us anything at all about the hospital’s cancer treatment quality. But a hospital that advertises these to an unsophisticated public may make lots of money! Caveat emptor.  

More insidiously, using 5 year survival rates may put marketing pressure on hospitals and carriers to widen our definition of ‘cancer’ beyond utility and label more women as having cancer; it’s a way to create more patients. This actually happens! Today, for example, about 25% of breast cancer diagnoses are for DCIS – ductal carcinoma in situ – an abnormal collection of cells in the milk duct. It’s a low grade tumor, something between normal breast tissue and breast cancer, not really what we think of as life threatening breast cancer. Some cancer specialists including Dr. Brawley of the American Cancer Society want to remove ‘carcinoma’ from the name – i.e. not call it cancer at all – out of concern ‘that we are scaring a whole host of people that have ductal carcinoma in situ who make rash decisions because it’s called ‘carcinoma’–decisions that they wouldn’t make if it was more adequately described for what it truly is.’

An expert panel of the National Institutes of Health agrees, recommending that the word ‘carcinoma’ be deleted from this diagnosis.  

But hospitals, presumably, want to keep the name as-is to advertise their spectacular 5 year survival statistics and attract patients. Indeed, as our radiologic equipment detects smaller and smaller abnormalities, maybe some of these will be called a new type of ‘cancer’ under pressure from hospital marketers and lobbyists. A hospital, knowing all this, can advertise its (potentially non-existent) high quality medical care and charge high prices to unsuspecting patients. Prices tell us nothing about quality…or lack thereof.

Consider delivery prices at two hospitals. Hospital A costs $4000 for a normal, vaginal delivery and $8000 for a C-section. Hospital B costs $4500 for the vaginal and $8500 for the C-section. Both have similar delivery volumes and first class NICUs. Hospital A is obviously cheaper and is, perhaps, the reference hospital in a reference based pricing system.

But Hospital A performs 48% of its deliveries by C-section, while Hospital B only performs 21%. The same woman would have a 27% increased likelihood of delivering by C-section at Hospital A.

Here’s the correct way to calculate the average delivery costs at both hospitals (go ahead and try): Cost of vaginal delivery times the % of vaginal deliveries plus Cost of C-section times the % of C-sections plus Number of extra days in the hospital for C-sections times the cost/day plus the infant and maternal readmission rate for C-sections times the cost per day times the % of deliveries by C-section plus the infant and maternal readmission rate for vaginal deliveries times the cost per day times the % of vaginal deliveries plus etc.

____________________________________

50 Latin for Let the Buyer Beware. Fine advice if the buyer has the relevant tools to beware with!


That’s why I suggest that shopping for medical services based on price is far more difficult than it initially appears and the effort may not bear any fruit at the end anyway.

This time, consider two breast cancer prevention drugs. 53 (I have no idea why I use so many breast cancer examples – perhaps because there’s so much breast cancer data around and examples abound.) Drug A – $20 copayment – reduces the number of breast cancers by only about 21 per 1000 women. It seems to fall into our ‘low quality’ care definition….1000 women need to take it for 21 to benefit. That’s only about a 2% effectiveness rate and 98% of women who take Drug A don’t receive any benefit from it.

But women who take the alternative, Drug T – with a $50 copayment – have 50% fewer breast cancers than women who don’t. This seems to fit our ‘high quality’ care definition much better. Cutting my chance of having breast cancer in half seems like a terrific deal for only $30 more/month, tax deductible in my Health Savings Account or Flexible Spending Account. A 50% reduction in breast cancer risk is a bargain at any price.

Here’s the catch: they’re the same drug, Tamoxifen. Taken prophylactically, it cuts women’s risk of developing breast cancer by about 50%, from about 43 to 22 per thousand. Sophisticated marketers can induce different kinds of consumer behavior by presenting medical information in different ways – a 50% cancer reduction is much more powerful than a 21 case reduction per 1000 women. The wise, sophisticated consumer will buy the $20 copayment drug and still enjoy the 50% breast cancer risk reduction….while the unsophisticated one may spend an unnecessary $360 per year, presumably for many years.

Again, simply having medical pricing information tells you nothing at all about quality. But you need medical care quality information to make wise consumption decisions. In short, the extent to which Consumer Driven Healthcare focuses on medical prices is the extent to which it fails to help people make medical decisions based on care quality. But as we’ve seen, decisions made on care quality tend to save money – in addition to helping patients get the best care, which is obviously the goal in the first place.

Of course, pricing information along with medical care quality information can be very useful to patients. Unfortunately, we have, today, little useful quality information.

Process guidelines as quality information

The health insurance industry responded to the Institute of Medicine’s To Err is Human report and the NCQA studies showing big treatment quality differences among hospitals and physicians by developing new sets of process guidelines. These are like manuals designed to improve clinical practice. The National Committee for Quality Assurance (NCQA) in particular developed the HEDIS guidelines – the Healthcare Effectiveness Data and Information Set - basically instructions for how to provide high quality medical care to various types of patients. Today, according to the NCQA website, the HEDIS tools are used by more than 90 percent of America’s health plans to measure performance of their contracted hospitals and physicians. Because so many plans collect HEDIS data, and because the measures are so

53 These examples are apparently true, from a lecture by Dr. Gilbert Welch, The Two Most Misleading Numbers in Medicine, Feb, 2012, viewed on You Tube. I made up the copayment amounts arbitrarily.
specifically defined, the NCQA claims that HEDIS makes it possible to compare the performance of health plans on an “apples-to-apples” basis. 54

The NCQA, for example, publishes lists of carrier rankings based on their contracted hospital and physician HEDIS scores. (I should point out that HEDIS is but one of a handful of measures. Another commonly used metric is CAHPS, the Consumer Assessment of Healthcare Providers and Systems, which also measures process compliance and has the same fundamental flaws as HEDIS, which I’ll describe below.) Note that HEDIS measures inputs, not outcomes. Inputs are what the doctor does to the patient; outcomes are how the patient actually did. HEDIS assumes that similar inputs lead to similar outcomes. Here are some of the 2013 HEDIS measures.55

<table>
<thead>
<tr>
<th>Measure</th>
<th>Commercial Patients</th>
<th>Medicaid Patients</th>
<th>Medicare Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assistance with smoking cessation</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Flu shots for adults over 50</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Annual monitoring for patients on persistent medications</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>

Others, perhaps less compelling:

<table>
<thead>
<tr>
<th>Measure</th>
<th>For Commercial Patients</th>
<th>Medicaid Patients</th>
<th>Medicare Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer screening</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Cervical cancer screening</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Colorectal cancer screening</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Use of Spirometry Testing in the Assessment and Diagnosis of COPD</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>

One specific concern: breast cancer screening with mammography is controversial, to say the least. The US Preventive Services Task Force only gives this a B recommendation, not A, concluding that ‘there is a moderate certainty that the net benefit is moderate’ Not exactly a ringing endorsement. The USPSTF recommends biennial, not annual mammograms due to the risk of false positives and breast cancer overdiagnosis, in women 50 – 75. They make no recommendation about mammograms for women 75

and older, saying the USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years or older.  

The Preventive Services Task Force actually disagrees with HEDIS about spirometry testing for COPD, recommending against screening adults for COPD using spirometry. HEDIS says ‘do it to increase your scores’; the USPSTF advises against saying ‘the incremental benefits are judged to be no greater than small’ and ‘fair evidence indicates that spirometry can lead to substantial overdiagnosis of COPD.’

I certainly can’t tell you whether spirometry testing is a good or bad thing and apparently, neither can the medical community. But doing it is necessary to get a good HEDIS score.

The fundamental point here: getting a high HEDIS score may not indicate medical care excellence. It may only indicate that your doctor checked the relatively easy-to-check boxes on one particular table of relatively easy-to-measure physician activities.

Michael Porter, Harvard Business School’s great strategy professor, explains this problem much more lucidly. Much more relevant is information about providers’ actual experience levels, the treatments they use...and, most importantly, the results they achieve. Porter’s concern – and yours, if you want good medical care – is that process compliance in medicine doesn’t always translate to outcome similarities. Process compliance means physicians treat similar patients similarly; Outcome metrics tell us how well patients actually did. In medicine similar medical processes can lead to different patient outcomes. (Sorry if this is difficult to grasp, but it’s really important to understand.)

A classic example of the difference between process compliance and patient outcomes comes from Atul Gawande’s study of cystic fibrosis. All CF treatments at all 117 specialized CF treatment centers across the country use exactly the same protocols for treating CF patients.

All CF physicians have the same specialized training. According to the theory underlying HEDIS, all CF patients should therefore enjoy about the same outcomes – lung function and longevity, for example. Unfortunately, patient outcomes vary significantly by CF treatment center, with some consistently overperforming and others consistently underperforming the norm.

Gawande graphed this as a classic bell curve of outcomes. Interestingly, Gawande learned that at least one facility regularly outperformed the norm, year after year. HEDIS type process metrics assume that this doesn’t happen. How can 117 facilities following exactly the same treatment protocols generate a bell curve of patient outcomes? Here’s Porter again: There are simply too many dimensions of process to track and too much heterogeneity among patients. Focusing on just a few visible process steps creates a checklist that providers can address, but oversimplifies the problem.  

56 [http://www.uspreventiveservicestaskforce.org/uspstf09/breastcancer/brcansrs.htm](http://www.uspreventiveservicestaskforce.org/uspstf09/breastcancer/brcansrs.htm)

57 [http://www.uspreventiveservicestaskforce.org/uspstf08/copd/copdrs.htm](http://www.uspreventiveservicestaskforce.org/uspstf08/copd/copdrs.htm)

58 Porter and Teisberg, Redefining Healthcare, page 54

59 Gawande, The Bell Curve in Gawande, Better

60 Porter, op cit, page 87
checklists only the easiest to measure processes not the most important. I suspect that’s what HEDIS and similar checklists do.

Some other problems

First, the HEDIS type checklists, as any process oriented checklists, become institutionalized, bureaucratized and resistant to change. The new medical information that constantly becomes available – the latest mammogram studies, for example – may not make it onto the HEDIS lists.

Or may make it after a lengthy time delay, during which even newer, potentially critically important data, becomes available. Process oriented checklists are often, if not always, at least somewhat out of date.

Yet physicians are often reluctant to deviate from the approved checklist. Their hospital administrators may sanction them for this.

Second, the designers of HEDIS type lists may become susceptible to industry lobbying. We have numerous examples in the medical care industry where experts who write regulations and who make recommendations are paid by pharmaceuticals or other suppliers to recommend their products. A classic example is the 2003 Adult Treatment Panel III, which lowered the definition of dangerous total cholesterol to 200. Eight of the 9 panelists had financial ties to pharmaceutical companies, most to companies that manufactured cholesterol-lowering drugs. One wonders how the designers of HEDIS style lists might be equally affected.

The information your clients really want

How will this treatment affect me? Will I get better? Will I be harmed? We call these outcome measures and the insurance industry is remarkably poor at providing these. Outcome measures describe how well patients actually do.

What percent of lung function do patients at a particular cystic fibrosis facility actually have? What is the average life expectancy at each CF facility? How many heart bypass patients need readmission to Hospital C within 30 days of discharge, and how many to Hospital D? How many TURP or hip replacement patients? Do patients having carpal tunnel surgery from Surgeon G return to work more quickly or less than patients of Surgeon H? And, even more basically, how many heart bypass surgeries, kidney removals, rotator cuff surgeries or hip replacements does a given hospital perform each year?

We have evidence that higher rates of a specific surgery by a specific medical team generate better outcomes, suggesting that the quantity of surgeries performed by a surgical team is a reasonable indicator of medical quality….but we often can’t get the quantity information. HEDIS style lists don’t provide it.

Porter gives this depressing summary:

---

In only a few isolated disease areas - notably cardiac surgery, organ transplants, cystic fibrosis and kidney dialysis - is broad-based results information available, and, most physicians lack any objective evidence of whether their results are average, above average, or below average.  

Fairly astonishing, don’t you think? This industry sector costs about $2.7 trillion per year and represents about 16% of the American gross domestic product. But we lack data indicating which medical professionals are the best, which are average and which are the worst.

In other words, most patients have no idea how good their physicians and hospitals are. Remember that half are below average, because, by definition, ‘average’ means that patient outcomes from half of all surgeons and at half of all hospitals are above it and half are below. Here’s Porter’s take on this: it is human nature for most people to believe that they are above average, which cannot be true, meaning you can’t just ask your doctor if he/she is above average because there’s no data to support the answer. Perhaps as a result of this mind-boggling lack of care quality information, the definition of a ‘good’ health plan is one that offers easy access to a wide range of physicians and the ‘best’ offers really easy access. This may be because of our poor outcome data. You want to try one doctor but, since you really don’t know if he/she is any good, you want the option to change.

Interestingly, we compare country healthcare systems on cost, longevity and infant mortality, but we compare carriers on provider network size, access ease and HEDIS scores. In doing so, we forget Kenneth Thorpe’s comments about ‘excess mortality’ and Elliott Fisher’s findings that easier access and more medical spending leads to slightly higher mortality rates, slightly poorer outcomes.

To escape these problems, people sometimes look at so-called consumer oriented physician rating services or social networking websites. A lot of these exist, all with about equally mediocre quality information.

HealthGrades, for example, claims that more than 200 million consumers use it to research and select a doctor or hospital and that it’s America’s most comprehensive source of information on hospitals and doctors.  

Atul Gawande once looked up his own HealthGrades report card: They don’t tell you that much. You will learn, for instance, that I am certified in my specialty, have no criminal convictions, have not been fired from any hospital, have not had my license suspended or revoked, and have not been disciplined for misconduct….it sets the bar a tad low, doesn’t it?

I looked up my own PCP and learned the following: 79% of patients would recommend him, He’s ‘very good’ at scheduling appointments, at office environment and at office friendliness, Most patients report that he listens well, helps patients understand their condition, spends enough time with patients and that they trust him. I suspect my auto mechanic would get the same write-up, word-for-word.

Surely there’s something about medical competence and patient outcomes that’s relevant here!

62 Porter, op cit, page 55

63 Porter, ibid

64 http://www.healthgrades.com/about

65 Better, page 207
Here’s what I didn’t learn, for example:

- Does he generally refer to aggressive specialists who operate as soon as possible on patients, or to more conservative ones who prefer to watch and wait?
- What percent of the orthopedic patients he refers for surgery need to be readmitted within 30 days of hospital discharge?
- What percent of cardiac? Urologic? Other?
- What percent of his female patients have mastectomies?
- What’s the average age of death of his patients with breast cancer? With prostate cancer?
- What percent of his male patients over age 65 have prostatectomies?
- What percent of his Medicare patients have leg amputations?
- What percent of his patients maintain their Body Mass Index within a couple of points through their 50s and 60s? Develop diabetes? Keep their blood pressure low-to-moderate? Have heart attacks? Maintain a full range of physical functioning and exercise regularly?
- What tests does he perform at annual physical? How open is he to discussing specific tests?
- And lots more similar info. Now that’s some really useful information on which to base a physician choice decision. Too bad it’s all unavailable.

The health insurance industry now requires that people spend their own money on medical care, perhaps $1000 or more annually, before insurance kicks in. We call this Consumer Directed Health Care. To aid consumers in this spending process, carriers publish medical care price lists from various providers. That helps them identify the least cost providers. The industry has developed metrics based almost entirely on medical process compliance to show consumers the ‘quality’ of various doctors and hospitals, though virtually none of those metrics include any outcome measures.

Neither the prices now available, nor process metrics like HEDIS, mean very much about medical outcomes. The insurance industry has failed to address the ‘up to about a third of medical spending generates no detectible benefit’ problem. Prices and process metrics fail to tell us which treatments are effective, which low quality, which unnecessary and which may do more harm than good.

Nor does the industry tell us which physicians are higher quality – above average in Porter’s terms – or below. Which generate excellent patient outcomes and which mediocre.

In fact, the insurance industry doesn’t even help patients determine which questions to ask. Does ‘appointment scheduling efficiency’ mean anything at all about patient care or outcomes? Should I spend my deductible on someone having a good HEDIS score…or someone who says the system is nonsense and, as a result, has a poor score but perhaps quite healthy patients?
Let’s conclude. If the insurance industry that developed Consumer Driven Healthcare and HEDIS type process metrics actually provides any useful patient education and decision support, then one of three things would happen:

*American healthcare spending would decrease relative to healthcare spending in other countries since our outcomes are not superior to theirs.* That has not happened. The trend is getting worse;

*American outcomes, as measured by longevity and other factors (infant mortality for example) would improve relative to other countries since our spending exceeds theirs.* That also has not happened over the past decade.

*Healthcare systemic harms would decrease relative to the harm caused by a lack of access / lack of insurance, since consumers would spend their healthcare money more wisely.* That also has not happened. Remember the mortality rates for uninsured Americans vs. insured folks who die from medical error that we presented at the beginning of this chapter. Our health insurance industry – part of what Harvard Medical School Professor Emeritus Arnold Relman once referred to as the medical-industrial complex – has failed to help patients differentiate high cost, low quality medical care from the opposite. Today’s patient may have a vague idea of his/her medical care costs but absolutely no idea the quality.

**Consumerism, Disclosure and Broker Responsibilities**

I would summarize our post-2000 insurance industry evolution as *placing more responsibility on consumers without providing information or tools to help them discharge that responsibility.*

We know, from extensive research, that health outcomes improve when patients are engaged in their own care and that people are eager to play a strong role in their own health care *when given the right tools.* But post-2000, the industry failed to provide those tools.

It acted, in our terms, unethically. It *let the buyer beware without doing your fellow a favor.*

Who, in our medical care landscape, can help consumers acquire the ‘right tools’?

I submit that a key candidate is the health insurance broker: Doctors are too busy to teach ‘tools’ while they diagnose, prescribe and treat. Carriers, for the reasons explained above, have basically dropped the ‘right tools’ ball, and hospitals, also for some reasons discussed above, tend to operate out of economic self interest and would be poor candidates to play this educational role.

Brokers, on the other hand, are the professionals who design benefits program at most companies and who communicate it to employees. They, I would argue, have the ethical responsibility to provide required ‘tools’ to their clients.

I hope this course helps brokers understand and accept that ethical responsibility.

---

66 Patients Charting the Course, US Institute of Medicine, 2011